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Sequential Designs for Individualized Dosing in Phase I Cancer Clinical Trials
Xuezhou Mao
This dissertation presents novel sequential dose-finding designs that adjust for inter-individual
pharmacokinetic variability in phase I cancer clinical trials. Unlike most traditional dose-
finding designs whose primary goals are the determination of a maximum safe dose, the
goal of our proposed designs is to estimate a patient-specific dosing function such that the
responses of patients can achieve a target safety level.
Extending from a single compartment model in the pharmacokinetic theory, we first
postulate a linear model to describe the relationship between the area under concentration-
time curve, dose and predicted clearance. We propose a repeated least squares procedure that
aims to sequentially determine dose according to individual ability of metabolizing the drug.
To guarantee consistent estimation of the individualized dosing function at the end of a trial,
we apply repeated least squares subject to a consistency constraint based on an eigenvalue
theory for stochastic linear regression. We empirically determine the convergence rate of the
eigenvalue constraint using a real data set from an irinotecan study in colorectal carcinoma
patients, and calibrate the procedure to minimize a loss function that accounts for the dosing
costs of study subjects and future patients. When compared to the traditional body surface
area and an equation based dosing methods, the simulation results demonstrate that the
repeated least squares procedure control the dosing cost and allow for precise estimation of
the dosing function.
Furthermore, in order to enhance the generality and robustness of the dose-finding de-
signs, we generalize the linear association to a nonlinear relationship between the response
and a linear combination of dose and predicted clearance. We propose a two-stage sequen-
tial design, the semiparametric link-adapted recursion, which targets at individualizing dose
assignments meanwhile adapting for an unknown nonlinear link function connecting the re-
sponse and dose along with predicted clearance. The repeat least squares with eigenvalue
constraint design is utilized as the first stage, and the second stage recursively applies an it-
erative semiparametric least squares approach to estimate the dosing function and determine
dosage for next patient. The simulation results demonstrate that: at first, the performance
of repeated least squares with eigenvalue constraint design is acceptably robust to model
misspecifications; at second, as its performance is close to that of repeated least squares
procedure under parametric models, the semiparametric link-adapted recursion does not
sacrifice much estimation accuracy to gain robustness against model misspecifications; at
last, compared to the repeated least squares procedure, the semiparametric link-adapted
recursion can significantly improve the dosing costs and estimation precision under the semi-
parametric models.
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1.1.1 Phase I Cancer Clinical Trials
A phase I clinical trial is the earliest stage in clinical drug development, and is typically
carried out in a small number of subjects. The goal of phase I trials is to investigate toxicity
and pharmacokinetics (PK) of a new drug, in order to set the basis for later investigation
of efficacy. Since the phase I trial is the first step where subjects are treated experimentally
with a new drug, the safety and feasibility of the new treatment have the top priority among
its concerns.
For non-life-threatening diseases, phase I trials are usually conducted on healthy volun-
teers, as long as the expected toxicity is mild and can be controlled without harm. For
life-threatening diseases such as cancer and AIDS, phase I trials are conducted with patients
because of the aggressiveness and possible harmfulness of drug-related cytotoxicity, possible
systemic treatment effects, and the high interest in the new drug’s efficacy in those patients
directly. The instruction of methodology throughout this dissertation will be focused on the
phase I cancer trials.
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Traditional phase I trials of a novel anticancer drug aim to determine a maximum safe
dose along with standardized treatment schedule for further investigation in later phases.
The dose is the so-called maximum tolerated dose (MTD), which is a maximum test dose
that does not exceed an acceptable level of toxicity. Most dose-finding designs for phase
I cancer trials assume that there exists a monotone dose-toxicity and dose-tumor response
relationship, such that the higher the dose level is, the drug is not only more effective but
also more toxic.
In the context of traditional phase I trials, the primary endpoint Y is usually a binary
indicator of occurrence of the dose limiting toxicity (DLT), with a pre-specified target toxicity
rate θ ∈ (0, 1); and, the dosage X usually takes values from a pre-selected set of discrete
dose levels denoted by D = {dk, k = 1, · · · , K} with dk < dk+1. In the rest of Chapter 1, if
without special indication, the aforementioned notations will be used continuously.
Definition 1 (MTD–surrogacy perspective) MTD from a surrogate-for-efficacy perspec-
tive, denoted by ν, is defined as the dose level with toxicity probability closest to the target
probability θ, that is ν = arg mindk∈D |pk − θ|, where pk = P (Y = 1|X = dk).
According to the surrogacy perspectives definitions, the major statistical issue in the
dose finding of traditional phase I cancer trials, is the estimation of MTD, which can be
identified as a percentile estimation problem. Several commonly used dose-finding designs
will be briefly summarized in Section 1.2.
1.1.2 Pharmacokinetics of Phase I Trials
An important but often neglected secondary objective of a phase I trial is the Pharmacoki-
netics, which investigates the absorption, distribution, metabolism and excretion of a drug
in human body. All drugs share a common feature that they are formulated to have effects
on some body system. In oncology, the effects include shrinking the size of a tumor, reduc-
ing the tumor growth rate, and protecting non-cancer cell from potentially harmful effects
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of chemotherapy. Pharmacokinetics studies what happens to drugs once they enter human
body, which often will entail drawing blood samples to measure the concentration of the
compound, possibly along with metabolites, over time. Important PK parameters include
the plasma concentration, area under the concentration-time curve (AUC), and clearance,
where AUC measures a subject’s overall exposure to a drug and clearance quantifies a sub-
ject’s ability of eliminating a drug. The PK measurements can be either incorporated into
the dose-response model as a covariate or utilized to define the primary endpoint.
The relationship between drug concentration and time is often characterized by a system
of differential equations, which is the so-called compartment model. These differential equa-
tions describe the instantaneous change in drug concentration or drug metabolites within
each compartment, with direct or indirect communication among compartments. The com-
partments in the model are based on the notion that, the drug circulates through human
body in the blood stream and may visit other parts of the body before it is eliminated. The
plasma or blood compartment may be considered as the central compartment for a drug
that is infused intravenously though, the drug will likely pass through the liver, kidneys,
the tumor hopefully, and then returns to the plasma from which it is eliminated at last.
The transit between plasma and the other organs forms part of the system of differential
equations characterizing the change in concentration over time.
Most anticancer drugs share a common feature that their therapeutic dosage windows
are narrow. In the past decades, the rapidly growing understanding of the pharmacokinetics
of anti-cancer drugs via the PK models enable us with exactly distinguishing the abilities
of eliminating drug metabolites among different patients. In the presence of large inter-
individual PK variability, if all patients are still treated at a common dose, they could be
either overdosed or underdosed. Both would cause sever ethical issues, as the former would
lead to unacceptable toxicities in some patients and the latter would result in insufficient
efficacy for some others.
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Therefore, if the potential inter-individual PK variation could be taken into consideration
when determining doses for patients, then a patient-specific maximal tolerated dose could
be recommended to ideally reduce ethical issues along with the traditional “one-size-fit-all”
dosing concept. This is one major motivation of the development of individualized dosing
methods for phase I cancer clinical trials.
1.2 Review of Dose-Finding Designs for Phase I Can-
cer Trials
The dose-finding designs for traditional phase I cancer trials usually allocate MTD within
a set of discrete dose levels D = {dk, k = 1, · · · , K}, which is specified in the planning
stage of the study. Typically in a sequential manner, a trial begins with a small number of
patients been treated at a starting dose, and decision to escalate or not depends on a dosing
algorithm that adapts to the occurrence of toxicity events. When a dose level is reached
with unacceptable toxicity, then the trial is stopped. In this section, the basics of frequently
used dose-finding designs for phase I cancer trials will be introduced. A comprehensive and
in-depth review of can be found in Cheung [2011].
1.2.1 The 3+3 Algorithm
The method (see Table 1.2.1) starts a trial at a low dose and escalates after every 3 to 6
patients per dose; the recommended dose is defined as the largest dose with fewer than 2
patients experiencing a predefined dose limiting toxicity (DLT) during the first course of
treatment.
At present, the 3+3 algorithm is still the most widely used design in practices, mainly
because of its simplicity and feasibility. Since the dose escalation rules can be tabulated
before a trial starts, the clinical investigators can make dose decisions during a trial without
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the help from a statistician.
Table 1.1: The Traditional 3+3 Algorithm
n1 Number of DLT Action
3 0 Escalate to the next higher dose di+1
3 1 Treat 3 additional patients at the current dose di
6 1 Escalate to the next higher dose di+1
3 or 6 ≥ 2 Stop escalation and terminate the trial
The MTD is estimated by the dose immediately below
the terminating dose
However, the 3+3 algorithm has many limitations. For instance, it tends to treat many
patients at a low and inefficacious dose, due to the conservative escalation scheme, and thus
has significant ethical issues. The 3+3 algorithm has no statistical justification. There is
no intrinsic property in the method to stop escalation at any given percentile, and hence
the distribution of MTD depends arbitrarily on the underlying dose-toxicity curve and the
number of test doses. Moreover, it is obvious that the 3+3 algorithm overlooks any possible
between-subject heterogeneity.
1.2.2 Continual Reassessment Method
The continual reassessment method (CRM) [O’Quigley et al., 1990] is the first model-based
design in dose-finding methodologies for phase I cancer clinical trials. Depending on the
estimation methods, there are generally two types of CRM designs: the one-stage Bayesian
CRM and the two-stage maximum likelihood CRM. In this section, we briefly introduce
the one-stage Bayesian CRM as an example, and more systematic reviews can be found in
Cheung [2011].
The toxicity probability of the binary toxicity response π(x) = P{yi = 1|x} is assumed a
monotone increasing function in dosage x. The trial objective is to determine the dose level
that is associated with a target toxicity rate θ. CRM postulates the true dose-toxicity curve
1n is the cumulative sample size.
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π(x) to be F (x, β0) for some true parameter value β0, and requires F (x, β) to be strictly
increasing in the dose x.
One of the most commonly used link functions in CRM is the one-parameter logistic
function
F (x, β) =
exp(a0 + βx)
1 + exp(a0 + βx)
,
where the intercept a0 is a fixed constant, and the parameter β is restricted to be positive
in order to ensure an increasing dose-toxicity relationship.
CRM launches a trial by treating the first patient at a pre-determined starting dose
x1, which is believed to have the closest toxicity probability to the target rate θ based on
existing knowledge. Each subsequent xi is determined sequentially based on all the previous
observations {(xj, yj) : 1 ≤ j < i}, such that
xi = arg min
dk∈D







is the posterior mean of β given the current data, β is








1− F (xj, β)
]1−yj}
.
The sequential dose allocation procedure is continued until a prespecified sample size n is
reached, and the estimated MTD recommended by this CRM trial is xn+1.
In words, CRM attempts to treat each patient at the current best estimate of MTD, that
is a dose whose corresponding estimated toxicity probability is the closest to the target rate
θ among all dose levels.
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1.2.3 Escalation with Overdose Control
The escalation with overdose control (EWOC) design takes the notions of continual reassess-
ment method, but estimates MTD with respect to an asymmetric loss function that places
larger penalty on overdosing than underdosing.
For a given α ∈ (0, 1), the loss function is defined as follows
Lα(x, ν) =
 α(ν − x), if x ≤ ν, that is, if x is an underdose(1− α)(x− ν), if x > ν, that is, if x is an overdose.
where ν is true MTD and α ≤ 0.5 usually. The loss incurred by treating a patient at δ units
above the MTD is 1− αα times greater than the loss associated with treating the patient at
δ units below MTD. For each subject, EWOC minimizes the Bayesian risk with respect to
the above loss function







where Ei(.) is the expectation with respect to the posterior distribution of MTD ν given the
current observations.
1.2.4 Stochastic Approximation
A nonparametric dose-response model is considered as follows:
Yi = M(Xi) + εi,
where the regression function M(x) = E(Y |X = x) is continuously differentiable in a neigh-
borhood of x0, denoted as B(x0), and has a unique root x0 at a target mean level θ such
that M(x0) = θ with M
′(x0) = β > 0, and the random errors {εi} are i.i.d. with zero mean
and finite variance σ20. In the special case when Y is a binary toxicity response and X is
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the dose level, the regression function is equal to the toxicity probability at a dose, that is,
M(x) = π(x) = P (Y = 1|x).
Robbins and Monro [1951] introduce the first stochastic approximation method to address
the problem of sequentially approaching the root to M(x) = θ. The procedure starts the
trial at a pre-specified dose level x1 = d1, and approaches x0 with successive approximation
xi for i > 1 recursively. The main idea of the Robbins-Monro procedure is to approximate
the regression function in B(x0) by the first order Taylor expansion:
M(x) ≈M(x0) +M ′(x0)(x− x0) = θ + β(x− x0), ∀x ∈ B(x0),
Then, based on the approximation yi = θ + β(xi − x0), there is x0 = xi − 1β (yi − θ), which
leads to the following recursion







for some constant b > 0 that is chosen by investigators.
The Robbins-Monro procedure is a nonparametric method. Under mild assumptions
about the regression function M(x) and the response Y , it can yield a consistent sequence
such that xi










Lai and Robbins [1979] modify the Robbins-Monro procedure via replacing b with a
consistent estimator of β, which is b̂n obtained by recursively applying the least squares fit
to the current observations {(x1, y1), · · · , (xn, yn)}.





where b̂i = max{b,min(β̂i, b̄)} with pre-selected lower and upper bounds b and b̄. Lai and










1.3 Review of Individualized Dose-Finding Designs for
Phase I Cancer Trials
By suggesting a common MTD to all subjects, the traditional dosing concept does not
allow for potential between-individual differences in susceptibility to a drug. Moreover,
MTD is commonly defined with respect to clinical toxicity, however, it becomes increasingly
important to consider biomarker expression or PK endpoints, with the use of molecular
targeted therapies that demonstrate large PK variability.
Recent improvements in understanding drug metabolism have triggered the development
of novel dose-finding designs that can accommodate inter-patient variation in drug tolerance.
The basic idea of individualized dosing in early phase cancer trials is to find a dosing al-
gorithm based on baseline characteristics that are believed to alter susceptibility to a drug.
Instead of a constant MTD, an individualized trial aims at achieving a patient-specific dosing
function, which depends on prognostic covariates and corresponds to a target response level.
For example, O’Quigley et al. [1999], O’Quigley and Paoletti [2003] and Ivanova and
Wang [2006] propose designs that determine dosage adjusted for prognostic group-level dis-
tinction. Also, Piantadosi and Liu [1996] and Babb and Rogatko [2001] develop designs
that individualize dose assignments while adjusting for measurable patient-specific charac-
teristics, such as the PK measurements or ancillary pre-treatment information, in order to
attain a target drug exposure. Potential benefits of these individualized dosing approaches
include: the improvements in both safety and efficacy of the new treatment, enhancing the
accuracy of dose escalation and dose-response model estimation, as well as the flexibility of
dose recommendation in terms of allowing for adjustment with individual patient needs.
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1.3.1 Two-Sample Continual Reassessment Methods
In phase I cancer trials, it is common that patients are categorized into two or more sub-
groups, for example, according to either age categories or some previous treatment status,
which is known to be related to individual tolerability to the new treatment. O’Quigley et
al. [1999] extend the continual reassessment method to determine the target dose levels for
two potentially heterogeneous patient subgroups, which is the so-called two-sample CRM.
The notions regarding the response and dosage all remains the same as those of CRM.
The target toxicity rates for the two subgroups are assumed to be the same, that is θ ∈ (0, 1).
The set of dose levels D = {dk, k = 1, · · · , K} are also assumed to be the same for the two
subgroups. An extra covariate G is introduced to as a subgroup indicator.
The true dose-response curves for the two subgroups are modeled as follows:
π1(x) = P (Y = 1|X = x,G = 1) = ψ1(x, β),
π2(x) = P (Y = 1|X = x,G = 2) = ψ2(x, β, b),
where (β, b) is a pair of parameters. The parameterization reflects that the two groups share
a common β, while distinguish from each other in the parameter b. The functions ψ1 and ψ2
should be selected to ensure the existence of the solutions to ψ1(x, β) = θ and ψ2(x, β, b) = θ










) , β > 0 and a0 is some known constant,





1 + b exp
(
a0 + βx
) , β > 0, b > 0 and a0 is some known constant,
where the second curve represents a shift from the first one.
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)1−yi]1(Gi=1)[ψ2(xi, β, b)yi(1−ψ2(xi, β, b))1−yi]1(Gi=2) .
whose maximizers are denoted as (β̂k, b̂k). Both the Bayesian methods and maximum likeli-
hood methods could be used to estimate the parameters.
If the (k + 1)th patient belongs to subgroup 1, the recommended dose for him/her is
xk+1 = arg min
x∈D
∣∣ψ1(x, β̂k)− θ∣∣.
If the (k + 1)th patient is in subgroup 2, then, the recommended dose for him/her is
xk+1 = arg min
x∈D
∣∣ψ2(x, β̂k, b̂k)− θ∣∣.
In some cases, investigators can somehow anticipate the ordering between two prognostic
subgroups in the trial, for instance, the younger patient group is known to have better
tolerance to aggressive treatments. O’Quigley and Paoletti [2003] further extend the two-
sample CRM to account for the anticipated ordering information between the two subgroups.
The main idea is to assign more aggressive starting dose to group 2 after the trial has begun
with the patients in group 1, given that group 2 is known to be more robust to toxicity
than group 1. In practice, such design could be realized via imposing a design restriction
such that dose allocation in group 2 must be at least equal to the dose currently allocated
in group 1, meanwhile allowing dose-skipping in group 2 but not in group 1.
1.3.2 Nonparametric Dose-Finding Design with Ordered Groups
Ivanova and Wang [2006] propose a nonparametric design to compete with the ordered two-
sample CRM in separately determining MTDs for two subgroups with possibly different
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susceptibility to toxicity.
The notations of this section remain the same as those for the two-sample CRM, only
except for that the toxicity probability πij = P (Y = 1|X = dj, G = i) is assumed to be
non-decreasing in doses within each group, such that πi1 ≤ · · · ≤ πiK for i = 1, 2. And it is
supposed that, the observations of the first m1 patients in group 1 and the first m2 patients
in group 2 are available yet, where group 1 has escalated to dose dk1 meanwhile group 2 has
reached dose dk2 . The proportion of toxicity responses at dose dj in group i is denoted as
π̂ij, and Ψ̂ = {π̂ij} is denoted as the matrix of these proportions as follows
Ψ̂ =
 π̂11, · · · , π̂1k1 ,NA, · · · ,NAπ̂21, · · · , π̂2k2 ,NA, · · · ,NA
 ,
where NA means ”currently not available”.
If group 2 is more tolerable to the treatment than group 1, denoted as G2 ≤ G1, then the
bivariate isotonic regression would be performed to obtain an isotonized toxicity proportion





j = 1, · · · , K, and π(2,1)i1 ≤ · · · ≤ π
(2,1)





















Similarly, if group 1 is more tolerable than group 2, denoted as G1 ≤ G2, then the
bivariate isotonic regression would be performed to obtain Ψ(1,2) = {π(1,2)ij }: the elements of




2j , j = 1, · · · , K, and π
(1,2)
i1 ≤ · · · ≤ π
(1,2)





















Bt comparing M (2,1) with M (1,2), the toxicity probability estimators corresponding to the
12
best fit would be selected as the final estimators, that is Ψ∗ = {π∗ij}.
Then, for the (m1 + 1)th patient in group 1, the dose would be:
xm1+1 = dk1+1I{π∗1k1 ≤ θ −∆}+ dk1−1I{π
∗
1k1
≥ θ + ∆}+ dk1I{θ −∆ < π∗1k1 < θ + ∆};
Similarly, for the (m2 + 1)th patient in group 2, the dose would be:
xm1+1 = dk2+1I{π∗2k2 ≤ θ −∆}+ dk2−1I{π
∗
2k2
≥ θ + ∆}+ dk2I{θ −∆ < π∗2k2 < θ + ∆},
where θ is the target toxicity rate and ∆ ≥ 0 is a pre-specified design parameter.
Upon the trial stops as it reaches a given number of patients, the MTD in group i is
estimated by dk(i), where k(i) = arg min1≤j≤νi |π∗ij − θ| for i = 1, 2, and νi is the maximum
index such that there are subjects in group i assigned to dose dνi but no subjects are assigned
to doses above dνi .
1.3.3 Individualized Continual Reassessment Method
Piantadosi and Liu [1996] extend CRM to incorporate an ancillary PK measurement (AUC)
into the adaptive dose-escalation design. AUC measures the overall exposure to a drug, and
should be positively associated with the toxicity of an anti-cancer drug. The motivation
of the proposed method includes that both PK information and dosage are important in
predicting toxicity response, and CRM can indeed explicitly account for PK measures within
dose escalation via a parametric model.
The response Y is a binary toxicity indicator with a target toxicity rate θ, while the
dose X is assumed to take values in a continuous range. The additional covariate Z (AUC)
is obtained from a two-compartment PK model, which postulates the transit of drug from
blood to a tissue compartment and elimination from blood to have linear kinetics.
Based on the two-compartment model, there could be derived out the following PK
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However, due to PK measurements are only available after patients take the treatment.
Therefore, in order to adjust for AUC, the authors estimate AUC by zi =
r0t0
γ + εi, where
r0 is the constant rate at which the drug is administered by continuous intravenous infusion,
t0 is the duration from the beginning of infusion to the stopping time that one is usually
administered in the trial, and ε is a random error.
Given the estimated AUC, the dose-response curve is modeled in a parametric form with




∣∣x, z} = exp{β0 + β1x+ β2∆Z}
1 + exp
{
β0 + β1x+ β2∆Z
} ,
where ∆Z = z − xγ , β0 is assumed to be known, β1 > 0 and β2 > 0. In words, if either
the dose or the residual between the estimated AUC and the true value increases, then the
toxicity probability should also increase.
The authors apply the Bayesian method rather than the maximum likelihood procedure
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where the joint prior of β1 and β2 was chosen to be a bivariate uniform density f(β1, β2).
The dose escalation scheme is as follows: the first m1 patients receive the starting dose
x1 that is chosen by the investigators according to pre-clinical studies. At the second, upon
the response and AUC are observed, the parameters β1k and β2k will be estimated using the
first k observations. Then, the dose for next mk+1 patients can be calculated by inverting
the model equation.
xk+1 =
logit(θ)− β0 − β̂2k∆Zk
β̂1k
The process is repeated until either the new dose no longer changes or a pre-specified sample
size is reached.
In the simulation, the authors compare the individualized CRM with the traditional
CRM, and find that the dose-finding scheme adjusted for PK data does not result in dra-
matic improvement in all circumstances, in terms of the biases of recommended doses. The
proposed method is superior to CRM only when the variability of AUC estimates or the
elimination rate γ is comparatively high to that of dose. And, only when AUC data are
important in predicting response and also variable enough so as to uncouple from dose, the
proposed method would perform significantly better than the traditional CRM.
1.3.4 Individualized Escalation with Overdose Control
Babb and Rogatko [2001] extend EWOC to adjust dose levels of PNU treatment according
to plasma concentration of anti-SEA antibodies for patients with advanced adenocarcinomas
of gastrointestinal origin. MTD is defined as a increasing function ν(z) of the anti-SEA anti-
bodies concentration Z, which is measured three days prior to the onset of PNU treatment.
PNU dose level is represented by the random variable X, meanwhile the response is a binary
toxicity indicator Y with a target toxicity rate θ. After observation of k patients, the history
data is Hk = {(xi, yi, zi) : 1 ≤ i ≤ k}.
Unlike the two-effect model employed by Piantadosi and Liu [1996], Babb and Rogatko
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[2001] propose a varying coefficient dose-response model to incorporate the covariate. Under










By specifying the following particular forms for the coefficient functions
 a(z) = a+ δ ln(z), assuming δ < 0,β(z) ≡ β, assuming β > 0,




∣∣x, z} = exp (a+ δ ln(z) + β ln(x))
1 + exp
(
a+ δ ln(z) + β ln(x)
) .
Based on the above model, the joint likelihood given the first kth observations Hk is





i=1 yi + δ
∑k








a+ δ ln(zi) + β ln(xi)
}] .
Thus, given the target toxicity rate θ = 0.1, then MTD can be derived out as
ν(z) = (9ea)−1/βz−δ/β,
which indicates MTD is increasing in the anti-SEA concentration given that δ/β is con-
strained to be negative. Prior to the PNU trial, a preliminary study is necessary for find-





, where MTD ν(z) will be searched for.
Upon the marginal posterior distribution of MTD ν(z) is derived out given Hk, which is
denoted as πz(ν|Hk) for any fixed z ∈ [c1, c2], then the dose for the (k + 1)th patient is
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∣∣Hk) is the expected posterior loss associated with any fixed dose
x ∈ Γ(zk+1). Like the loss used in EWOC, the asymmetric loss function is defined as, for a
given α ∈ (0, 1) and any fixed z ∈ [c1, c2],
lz(x, ν(z)) =
 α(ν(z)− x), if x ≤ ν(z), that is, if x is an underdose(1− α)(x− ν(z)), if x > ν(z), that is, if x is an overdose.
The loss criterion implies that, for any ∆ > 0, the loss incur by treating a patient at ∆ units
above MTD is 1− αα times greater than the loss associated with treating the patient at ∆
units below MTD. Low value of the threshold α would result in a cautious escalation scheme
with relatively small increments in dose, while high values would lead to a more aggressive
escalation.
Consequently, by the conclusion of the PNU trial, each patient received a dose level
corresponding to the best estimate of MTD given the historical data. The flexibility that
the dose-finding design and dose-response modeling gain via allowing dose levels to adjust
for patient-specific needs is intuitively obvious.
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1.4 Motivations
1.4.1 Literature Review Discussions
First of all, the proposals reviewed in Section 1.3 aim at a target toxicity rate of either
binomial or multinomial events while adjusting for patient’s risk. In fact, rather than limited
to phase I designs, there is also individualized dose-finding designs developed for phase I/II
trials, for instance, Thall et al. [2008] consider a Bayesian method, called EffTox, based on
bivariate binary outcomes using probit models to depict the marginal dose-covariate-response
relationships.
While these proposals vary in model assumptions and decision rules, they attempt to
treat patients near the target dose. This type of approach, while ethically appealing, lacks
theoretical justification, for instance the consistency of recommended dose sequence. In case
of a homogeneous population, Cheung [2002] shows that applying the continual reassess-
ment method with a multiparameter model may yield a dose sequence converging to a limit
bounded away from the true target dose even if the model assumption is correct. The reason
for this phenomenon is that the dose sequence depends on patient outcomes and is random.
As such, there is no intrinsic mechanism to ensure that the design matrix will satisfy the
conditions for consistent estimation of the model parameters, and hence the target dose.
Therefore, we are motivated to develop an intrinsic mechanism for either traditional or in-
dividualized dose-finding designs, such that it can not only ensure consistent dose sequence
but also allow for precise estimation for the parametric dose-response models.
At the second, most existing individualized dose-finding designs are proposed for the
studies of traditional cytotoxic agents, where the primary endpoints are most often binary
toxicity responses. In the past decades, an emphasis shift from the traditional cytotoxic
agents to novel molecular targeted therapies in anti-cancer drug development has necessitated
the development of new phase I studies that considers a new type of primary endpoints.
18
Because, most molecular targeted agents are more selective and less toxic than cytotoxic
agents; and, the fundamental assumption that toxicity-based dosing methods rely on, that
the drug’s therapeutic and toxic effects of the drug increase in parallel as the dose is escalated,
could be violated for the molecular targeted agents [Booth et al., 2008]. At such cases, the
traditional binary toxicity response might not be an ideal primary endpoint for model-based
dose-finding approaches. Instead, new types of ideal primary endpoints should be considered
for phase I cancer trials, for example the PK responses due to their close connection to both
the dosage and safety endpoints [Fox et al., 2002].
So far, several approaches have been proposed to target at the expected value of a contin-
uous outcome. For example, O’Quigley et al. [2010] consider PK endpoint using an extended
continual reassessment method; Ivanova and Kim [2009] aim at a given mean of AGT pro-
tein in a glioma study based on t-statistics. To address multiple toxicities, Bekele and Thall
[2004] propose a Bayesian design that targets at the mean of a numerical toxicity burden;
in the sequel, Bekele et al. [2010] extend the idea to risk-specific dosing using average tox-
icity score. However, except for Bekele et al. [2010], which model toxicity within each risk
group, these previous works do not account for inter-patient heterogeneity, especially for a
continuous prognostic covariate. Thus, it is in need to develop the corresponding methods
for continuous PK responses while adjusting for inter-patient heterogeneity.
Moreover, many parametric model based dose-finding designs assume a known link func-
tion with a location and scale parameters between the toxicity responses and dosage, for
example the logistic link for CRM in Section 1.2.2. In real practices, the true links are never
known, however, the methods that are robust to link misspecification are seldom developed
for phase I dose-finding designs. This important but neglected problem has drawn recent
focus from researchers in phase I community, such as Warfield and Roy [2013]. For the
case of binary toxicity responses and discrete dose levels, Warfield and Roy [2013] propose a
semiparametric sequential dosing algorithm that aims at estimating the maximum tolerated
19
dose (MTD) with being robust against link misspecification. By assuming the unknown link
function is a cumulative distribution function from a continuous location-scale family, their
proposal essentially incorporates a univariate nonparametric binary regression into a sequen-
tial D-optimal design, but cannot be applied to adjust for additional prognostic covariates.
At present, for individualized dosing approaches, the robust designs can adapt for more gen-
eral model settings with unknown dose-response link functions are missing and worth efforts
in explorations.
1.4.2 Motivating Trial: the Irinotecan Study
Irinotecan is a topoisemerase I inhibitor that is approved as a first and second line treatment
of metastatic colorectal cancer. The metabolism of irinotecan and exposure to its active
metabolite SN-38 are influenced by several enzymes such as CYP3A4, whose expression and
function could be affected by numerous environmental and genetic factors [Mathijssen et al.,
2004]. Therefore, in the presence of large PK variability of metabolizing irinotecan among
the patient population, the traditional “one-size-fit-all” dosing concept could cause severe
ethical issues resulted from either overdosing or underdosing. For instance, on one hand, if
a subject whose ability of eliminating irinotecan is low but was treated at a high dosage,
then he/she could experience severe toxicity events; on the other hand, if a subject who has
strong ability of eliminating irinotecan but was treated at a low dosage, then he/she would
never receive sufficient treatment efficacy.
In order to control for inter-patient PK variability in dose determination, van der Bol et
al. [2010] compare two individualized dosing algorithms in a two-arm irinotecan study. They
use irinotecan as a single agent in 40 patients with metastatic colorectal cancer: 20 patients
are randomized to receive doses via an equation algorithm based on a single compartment
model, and the other 20 are dosed by the conventional body surface area (BSA) formula.
The primary endpoint of the irinotecan study is a continuous PK response (AUC), which
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measures a patient’s overall exposure to irinotecan. The dosage of irinotecan is continuous,
meanwhile there is also a continuous PK covariate (clearance), which measures individual
ability of eliminating a drug.
More precisely, let y be the logarithm of AUC of irinotecan, x be the logarithm of
irinotecan dose, and z∗ be the logarithm of irinotecan clearance. A single compartment
model states a PK relationship between AUC, dose and clearance such that
y = x− z∗. (1.2)
Since the study aims to achieve an AUC level of 22.157 µg× h/mL, based on the above
PK relationship, the equation based algorithm [van der Bol et al., 2010] prescribes a dose
according to the formula
x = t0 + z, (1.3)
where t0 = log(22.157) and z is the predicted clearance on log-scale based on the patient’s
phenotypes, including γ-glutamyltransferase, midazolam activity, and height [Ratain and
Innocenti, 2010]. Since the clearance as a PK measurement is only available after treatment,
van der Bol et al. [2010] use the predicted clearance instead in the equation dosing algorithm
(1.3). The rationale is that patients with higher predicted irinotecan clearance can tolerate
and should receive higher dose, so as to reach a target plasma concentration. As the control
arm, the patients treated according to the conventional BSA formula receive doses based on
x = log(350) + B (1.4)
where B is the logarithm of the body surface area of the patient.
As a result, van der Bol et al. [2010] find that the incorporation of predicted clearance
in dosing algorithm can lower the incidence of toxicity events. The descriptive statistics of
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irinotecan study are summarized in Table 1.2. The irinotecan data will be deeply utilized in
the simulation studies of this dissertation, and the BSA and equation based dosing algorithms
will be included in the design comparisons as individualized dosing approaches in present
clinical practices.
Table 1.2: Summary of the Irinotecan Data
Correlation with Significance (p-value)
Variable Mean Median S.D. Range x z B
y 3.05 3.01 0.26 [2.56, 3.76] 0.12 (0.47) -0.10 (0.53) -0.09 (0.60)
x 6.49 6.49 0.20 [5.94, 6.97] 0.67 (0.00) 0.63 (0.00)
z 3.44 3.46 0.26 [2.83, 3.85] 0.53 (0.00)
B 0.63 0.63 0.12 [1.36, 2.37]
1.4.3 Summary
In brief, motivated by the limitations of existing individualized dosing methods and the
irinotecan study, this dissertation research develops two novel individualized dose-finding
designs for phase I cancer trials, the repeated least squares procedure and semiparamet-
ric link-adapted recursion. Both designs are proposed for the cases with continuous PK
responses and continuous dosage, meanwhile there exists significant inter-individual hetero-
geneity in the ability of metabolizing a drug.
Under linear dose-response models, the proposed repeated least squares procedure deter-
mines dose according to individual ability of metabolizing a drug, the same time an intrinsic
mechanism guarantees the consistency of model parameter estimates and recommended dose
sequence. It sequentially applies least squares fit to estimate the dosing function, subject
to a consistency constraint based on an eigenvalue theory in the stochastic linear regression
established by Lai and Wei [1982] and Wei [1985].
The second major goal of this research is to develop a dosing method that can not
only adjusts for inter-individual PK variability, but is also robust to the misspecification of
dose-response link function. Thus, we further extend the linear model to a more general
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semiparametric model setting, where the response is associated with the linear combination
between dose and covariate via an unknown nonlinear link function. Under this model,
a novel semiparametric design is proposed to recursively estimates the dosing function by
utilizing an iterative semiparametric regression approach to estimate the link function and
direction parameter, so as to attain enhanced robustness against model misspecification.
The rest of this dissertation are organized as follows. Chapter 2 introduces the methods
of the repeated least squares procedure, which includes two distinct designs, respectively
without and with a consistency constraint. Chapter 3 introduces the calibration procedure
for the constrained design, and presents simulation studies on comparing two formula-based
individualized dosing algorithms with the proposed repeated least squares procedure under
the linear models. Chapter 4 extends the linear model to a semiparametric model, intro-
duces the method of our proposed semiparametric link-adapted recursion, and then presents
simulation studies on the comparison between the repeated least squares procedure and
semiparametric design in terms of dosing accuracy, estimation precision and robustness to
model misspecification. At last, Chapter 5 summarizes the contributions of this research
and discusses on its potential further extension work.
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Chapter 2
Repeated Least Squares Procedure
2.1 Linear Dose-Response Model
Throughout the rest of this dissertation, the notations will remain the same as those in
Section 1.4.2, such that y is the logarithm of irinotecan AUC with the target level t0 =
log(22.157), x is the logarithm of irinotecan dose, z is the predicted clearance on log-scale,
and B is the logarithm of body surface area (BSA).
The dosing algorithm (1.3) by [van der Bol et al., 2010] assumes that the predicted
clearance z is a perfect estimate of the true clearance z∗, which is not observable at baseline,
and that the PK characterization of irinotecan behaves according to the single compartment
model. While the study data show a plausible linear relationship between z∗ and z, that
is, z∗ = ψ0 + ψ1z + ε
∗, there is strong evidence to support that ψ0 6= 0 and ψ1 6= 1, as the
p-values of corresponding Wald tests are 0.023 and 0.024 respectively (see Figure 1(a)).
Motivated by both the theoretical PK relationship (1.2) and the linear relationship be-
tween z∗ and z, we propose a linear regression model to describe the relationship between
the AUC, dose and predicted clearance on the log-scale:
y = α + βx+ γz + ε (2.1)
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where ε is random noise with mean 0 and finite variance σ2.
The PK relationship (1.2) derived from a single compartment model would be a special
case of model (2.1) with (α, β, γ) = (0, 1,−1) (see Figure 1(b)). However, the least squares
fit to irinotecan data leads to an estimate (α̂, β̂, γ̂) = (1.26, 0.46,−0.34) and suggests that
(α, β, γ) 6= (0, 1,−1) is significant (Wald test p-value=0.026).
Figure 2.1: Fitting a Linear Model to the Irinotecan Data
In contrast, the linear model (2.1) appears to be more adequate for the irinotecan data,
compared to PK model (1.2). The residuals of single compartment model (see Figure 2.1(b))
are slightly larger than those of least squares fit (see Figure 2.1(c)); and, the residuals of
single compartment model generally decreases as fitted y grows, which pattern is shown by
a nonparametric smoothing curve between the residual and fitted y, however, the residuals
of least squares fit show no dependency on their fitted y. In fact, Figure 1(d) shows that
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the equation dosing algorithm (1.3) assigns lower doses than the that estimated by the least
squares fit, x = (t0 − 1.26− 0.34z)/0.46.
Based on the linear dose-response model (2.1), two individualized dose-finding designs
are developed for phase I cancer trials with continuous PK responses and dosage.
2.2 Unconstrained Repeated Least Squares Design
For an individualized phase I cancer trial, the trial objective is to estimate a patient-specific
dose x = θ(z) so that E(y|x, z) can achieve the target level t0, rather than the estimation
of MTD for the traditional phase I cancer trials. Under the model (2.1), this goal would be
equivalent to estimate the following dosing function
θ(z) =
t0 − α− γz
β
, for any given z ∈ Iz, (2.2)
where Iz = [zmin, zmax] is the proper range of z and θ(z) should take value within a pre-
specified dose range of x, that is Ix = [xmin, xmax].
The estimation of dosing function θ(z) involves the estimation of coefficients of model
(2.1). Thus, it would be natural to apply the least squares fit to obtain the estimates of
(α, β, γ), and then substitute them into θ(z). Due to the sequential manner of the design, the
estimation stated above is then conducted recursively as the trial proceeds. This is indeed
the main idea of the proposed repeated least squares (RLS) design.
Algorithm 1 (RLS)
1. For the (i+ 1)th subject, we at first estimate θ(z) by
θ̂i(z) =
t0 − α̂i − γ̂iz
β̂i
, for any fixed z ∈ IZ , (2.3)
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where (α̂i, β̂i, γ̂i)
′ is the least squares estimate using observations of the first i subjects;









3. Once yi+1 is observed, the least squares estimate of (α, β, γ) will be updated; the trial
continues with repeating Step 1 through 3 until a pre-specified sample size is reached.
It is worth to mention that, so as to ensure that the recommended doses take value within
the proper range Ix, the estimate doses are truncated by the lower and upper limits of the
dose range. At the trial’s end, an estimated dosing function θ̂n+1(z) will be recommended
to future patients.
The repeated least squares design is a straightforward approach to determine dose with
respect to individual predicted clearance under model (2.1). It is actually an extension of the
maximum likelihood recursion method [Wu, 1986] in the presence of an extra covariate. The
simplicity of RLS can give it good feasibility in practices, however, RLS does not necessarily
result in desirable estimation properties of the dosing function, because it is unable to exclude
the occurrence of asymptotic co-linearity to its design matrix.
Due to ethical issues, the primary concern on the theoretical properties of a dose-finding
design is the dosing accuracy over a trial. A consistent dose sequence, which is defined as
following, can ensure that the assigned doses would eventually approach the true dosing
function in a certain sense, and so avoid systematic dosing biases to happen during a trial.
Definition 2 (Strong Consistency of Dose Sequence) The recommended dose sequence
is strongly consistent for the true doses, if
∣∣xn − θ(zn)∣∣ a.s.−−→ 0, as n→∞. (2.4)
It can be shown that, as long as the strong consistency of least squares estimator (α̂i, β̂i, γ̂i)
′
holds, the estimated dosing function (2.3) converges point-wisely to the true dosing function
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(2.2) by the Continuous Mapping theorem, and thus the strong consistency (2.4) can be
further guaranteed.
However, the convergence rate of dose sequence can actually in turn affect the strong
consistency of the least squares estimator. If doses converge to some function too quickly, it
would cause columns of the design matrix to asymptotically have co-linearity. For simplicity,
if we consider the scenario with dose only but no other covariate, then a rapidly converging
dose sequence would cause that most dose values concentrate closely around a constant
and the dose column is nearly co-linear with the intercept column. This phenomenon is
described as the asymptotic singularity by Chen et al. [1999], which results in poor least
squares estimation essentially because the design fails to provide sufficient “information”.
The strong consistency (2.4) controls overall dose estimation precision of a trial and excludes
that systematic dosing errors happen to all subjects. Therefore, the dose convergence rate
of RLS needs to be controlled in order to eliminate the asymptotic singularity.
2.3 Repeated Least Squares with Eigenvalue Constraint
Design
Under the stochastic linear regression models, Lai and Wei [1982] establish a sufficient con-




a.s.−−→ 0, as n→∞, (2.5)
where λmax(n) and λmin(n) are respectively the maximum and minimum eigenvalues of
M ′nMn, and Mn is the design matrix of the first n subjects in least squares fit. Lai and Wei
[1982] point out by an example that, if the eigenvalue condition (2.5) is violated, the least
squares estimator would fail to be strongly consistent. This theorem along with the model
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settings, as well as the example and proof sketch are summarized in Section 2.5.
The essential reason of the inconsistency is the asymptotic singularity resulted from the
uncontrolled dose convergence rate. The eigenvalue condition (2.5) in effect slows down the
dose convergence rate by requiring λmin(n) to diverge faster than log λmax(n). As Frees
and Ruppert [1990] state that, spreading the design points so that they do not concentrate
around a target too rapidly can improve the precision of least squares estimation. Thus, the
importance of the eigenvalue condition (2.5) is to help the design gain sufficient information
by spreading design points apart, and thus eliminate the occurrence of asymptotic singularity
and guarantee precision of least squares estimator.
In general, without any control on the dose convergence rate, model based dose-finding
designs, such as RLS, do not necessarily result in a strongly consistent least squares estimator.
Therefore, a general principle is in need for ensuring estimation precision of a dose-finding
design. The eigenvalue condition (2.5) is such a principle.
Motivated by the eigenvalue condition (2.5), we propose the repeated least squares with
eigenvalue constraint (RLSEVC) design.
Algorithm 2 (RLSEVC)
1. For the (i + 1)th subject, we estimate θ(z) by θ̂i(z) =
t0 − α̂i − γ̂iz
β̂i
, for any given
z ∈ Iz;
2. Determine the dose xi+1 = arg min
x∈Ix
∣∣x− θ̂i(zi+1)∣∣ subject to an eigenvalue constraint
ρi+1(x, zi+1) ≤ ri+1, (2.6)
where the eigenvalue ratio ρn(x, z) =
log λmax(n)
λmin(n)
is a function of x and z, and the real
sequence rn is specified in form of rn = Cn
−δ1(log n)1−δ2 .
3. Upon yi+1 is observed, the least squares estimate of (α, β, γ) will be updated; the trial
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continues with repeating Step 1 through 3 until a pre-specified sample size is reached.
At the end of the trial, the estimated dosing function θ̂n+1(z) will be recommended to future
patients.
Particularly, C is a positive constant determined by an initial design, which will be intro-
duced in details in Section 3.3. The convergence rate of eigenvalue constraint is controlled
by the design parameter (δ1, δ2), which is selected from R = [0, 1) × [0,+∞) \ 0 × [0, 1] to
ensure that rn converges to 0. The form of the real sequence rn is actually not unique, as





under motivation of the eigenvalue condition (2.5). The numerator log n is the typical rate at
which the maximum eigenvalue λmax(n) in logarithm diverges to ∞, according to Theorem
2 of Wei [1985]; meanwhile, the denominator of rn is chosen to explicitly control the rate at
which it diverge faster than log n.
By construct, each single dose suggested by RLSEVC satisfies the eigenvalue condition
(2.5). Thus, RLSEVC naturally guarantees the strong consistency of least squares estimator
and hence that of the estimated dosing function.
2.4 Coherence Restriction
The concept of coherence is introduced to phase I dose-finding designs by Cheung [2005] in
the context of dose-escalation among a discrete range. Specifically, an escalation for a new
patient is defined to be coherent only when the previous patient does not experience toxicity
and a de-escalation is coherent only when previous toxicity is observed.
The coherence is a general principal to enhance practicality of a dose-finding design, under
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the motivation of ethical concerns in trial conduct. It is worth to be extended to designs for
individualized dosing. However, unlike the traditional dose-escalation, not only the response
of previous patient influences dose increase or decrease, but should the covariate value of
current patient also impacts enhancement or reduction in dose compared to the previous.
To account for both the influence of previous response and current covariate on dosage, we
propose a coherence criterion for individualized dose-finding designs in phase I cancer trials
as following.
Definition 3 (Coherence Restriction) For the (i+1)th subject, the following restriction
is applied to the individualized dose-finding procedure:
• If yi > t0 and zi ≥ zi+1, then xi+1 ∈ [xmin, xi];
• If yi > t0 and zi < zi+1, then xi+1 ∈ [xmin, xmax];
• If yi ≤ t0 and zi ≥ zi+1, then xi+1 ∈ [xmin, xmax];
• If yi ≤ t0 and zi < zi+1, then xi+1 ∈ [xi, xmax];
where a subject is considered to have toxicity if his/her yi exceeds the threshold t0.
For the irinotecan trial, the dose increase is coherent when the previous subject has
no toxicity and his/her predicted clearance is lower than the current subject’s; the dose
reduction is coherent when the previous subject has toxicity and his/her predicted clearance
is higher than the current subject’s. However, the definition of coherence becomes subtle
and complex, when the previous subject with lower predicted clearance has toxicity, or the
previous subject with higher predicted clearance has not experienced toxicity. For instance,
at the former case, even though the previous subject had toxicity, a higher dose could be
still safe for the current subject due to his/her stronger ability of eliminating irinotecan.
Therefore, for these two scenarios, no coherence restriction is imposed on dose-finding. It is
this freedom of individualized dosing that potentially benefits patients with higher efficacy
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and safety, because, in dose-determination for the current patient, previous outcomes are no
longer the only consideration, drug metabolizing capability of this patient will also play an
equally important role in the determination.
For RLSEVC, the eigenvalue constraint is the key to ensure an precisely estimated dosing
function, while the coherence restriction can further improve dosing accuracy without sacri-
ficing estimation precision; however, for RLS, the coherence restriction might only improve
dosing cost in the absence of asymptotic singularity.
2.5 The Eigenvalue Theorem and An Example
In this section, the eigenvalue theory by Lai and Wei [1982] will be briefly stated at first.
Then, an example will be showed that, in the presence of stochastic regressors, the least
squares estimator could fail to be strongly consistent when the eigenvalue condition (2.5)
gets violated.
Lai and Wei [1982] consider the following stochastic linear regression model,
yn = β1xn1 + · · ·+ βpxnp + εn, for n = 1, 2, · · · , (2.7)
where {εn} is a martingale difference sequence with respect to an increasing sequence of
σ-fields {Fn}, and xn = (xn1, · · · , xnp)′ is the vector of sequentially determined stochastic
regressors at the nth stage, such that xn depends on all the previous observations {(xi, yi)}n−1i=1
through certain sequential design, in other words xn is Fn−1-measurable.
Lemma 1 (Theorem 1 of Lai and Wei [1982]) Under the model (2.7), suppose that







∣∣Fn−1) <∞ a.s., for some q > 2. (2.8)
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Moreover, if the design levels xn1, · · · , xnp at stage n are Fn−1-measurable random variables
such that
λmin(n)
a.s.−−→∞, and log λmax(n)
λmin(n)
a.s.−−→ 0, as n→∞, (2.9)
where λmax(n) and λmin(n) are respectively the maximum and minimum eigenvalues of
X′nXn, and Xn = (x1, · · · ,xn)′ is the design matrix at stage n, then the least squares
estimate b̂n =
(






X′nYn converges to β = (β1, · · · , βp)′ almost
surely; and, in fact,
max
1≤j≤p
∣∣b̂nj − βj∣∣ = O({ log λmax(n)
λmin(n)
}1/2)
a.s. .  (2.10)
At most time, for sequential designs such as the stochastic approximation (1.1), λmax(n) =
O(n) almost surely, which is also shown by the Theorem 2 of Wei [1985]. Especially for our
proposed repeated least squares procedures, only the dose is a stochastic regressor while
the realizations of the other covariate are randomly sampled from a normal distribution,
thus λmax(n) should diverge typically at the rate n as the case of completely randomized
designs. Therefore, as in later literature such as Chen et al. [1999], the eigenvalue condition
(2.5) only requires the eigenvalue ratio between log λmax(n) and λmin(n) to converge to zero
almost surely, because it also naturally requires that λmin(n)
a.s.−−→∞.
As pointed out by Lai and Wei [1982], an important case of such martingale difference
sequence {εn} is independent random variables with zero mean. Thus, under our proposed
model (2.1), the independent and identically distributed normal random noises {εn} obvi-
ously satisfy the condition (2.8), since supnE
(
|εn|3
∣∣Fn−1) = E(|ε1|3) <∞. Under the model
(2.1), if the σ-field {Fn} is generated by {(Bi, zi, εi)}ni=1, then xn is Fn−1-measurable. There-
fore, if the eigenvalue condition (2.5) holds, then, according to the Theorem 1 of Lai and
Wei [1982], the least squares estimate (α̂n, β̂n, γ̂n)
′ is strongly consistent for (α, β, γ)′.
Example 1 (What if the Eigenvalue Condition is Violated)
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This example demonstrates that, if a sequential design does not have special control for the
dose convergence rate so that the eigenvalue condition (2.5) gets violated, then the recursive
least squares estimator could be inconsistent for the true model coefficients.
The following linear model is considered in this example:
yi = α + βxi + εi. (2.11)
where the random errors εi are independent and identically distributed with zero mean and
unit variance. The σ-field generated by ε1, · · · , εn is denoted as Fn = σ(ε1, · · · , εn). The
stochastic regressor xi is defined inductively by
x1 = 0, xn+1 = x̄n + cε̄n, n ≥ 1, (2.12)
where c 6= 0 is a real constant.














α̂n = ȳn − β̂nx̄n = α + (β − β̂n)x̄n + ε̄n. (2.14)
According to Example 1 of Lai and Wei [1982], the sequential design leads to an asymp-
totically co-linear design matrix such that the eigenvalue condition (2.5) is violated, and
both α̂n and β̂n fail to be strongly consistent for α and β respectively. The sketch of the
proof is as follows.
By Corollary 1 of Lai and Robbins [1979] and Lemma 1 of Lai and Robbins [1981],
n∑
i=1






























i ε̄i−1εi, n ≥ 1
}
is a martingale relative to the σ-fields Fn, based on the



















































Combining (2.13) and (2.18), we can get that β̂n
a.s.−−→ β − 1c .
Then, we will show that α̂n also fails to be strongly consistent for α. By induction, we




i . Now, suppose that it holds for xn, then

































































i < +∞ a.s..
Moreover, the Strong Law of Large Numbers leads to that ε̄n
a.s.−−→ 0. Then, by (2.12),











i < +∞ a.s., then by (2.14) and β̂n
a.s.−−→ β − 1c ,
α̂n = α + (β − β̂n)x̄n + ε̄n
a.s.−−→ α + S.
At last, let us look at what happens to the eigenvalue condition of the design matrix. Let
xi = (1, xi)
′, Xn = (x1, · · · ,xn)′, and λmax(n) and λmin(n) be the maximum and minimum
eigenvalue of X′nXn respectively.





























The limit is not zero, which violates the eigenvalue condition (2.5). 
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Chapter 3
Applications of Repeated Least
Squares Procedure
3.1 Loss Criteria
Due to ethical concerns, most dose-finding designs assign the “best” estimated dose to the
next patient based on historical data, so as to lower the dosing costs for enrolled subjects as
largely as possible. These so-called “best-intent” designs share a common limitation that is
overlooking the potential costs of dosing future patients.
To reduce future dosing costs, an individualized dose-finding design cannot do better
than estimating the dosing function as precisely as possible. As stated in Section 2.3, design
points need to be spread out to ensure the precision of least squares estimator and the strong
consistency of dose sequence. Thus, a key to implement RLSEVC is to choose convergence
rate of the eigenvalue constraint, which indeed controls the extent of spreading design points
apart. A slow-converging constraint would contribute little to spreading design points, and
lead RLSEVC to be equivalent to RLS; a fast-converging constraint would force design points
to be far away from the “good” doses, and cause large dosing cost. Therefore, the goal of
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design calibration is to identify out an “optimal” pair of (δ1, δ2) for RLSEVC, so that it can
balance dosing costs of current subjects and future patients.
Definition 4 (Dosing Cost) In the light of Lai and Robbins [1979], the total dosing cost








where n is the sample size of a trial.
Definition 5 (Integrated Squared Error) The accuracy of the estimated dosing func-








where p(z) is the normal density of predicted clearance on log-scale (z).
In other words, the dosing cost measures the overall expenses that all n subjects of the
current trial would pay for, while ISE indeed measures the potential dosing cost for a single
patient who will be dosed using the estimated dosing function in the future.
To account for the two sources of dosing costs, we propose a two-element loss function












(j) is the mean integrated squared error across all simulated trials, and κ (> 0)
is the ratio of a future trial’s size compared to the current sample size. Since Dn measures
dosing cost for n current subjects, by timing κn to MISE, we intend to balance the contri-
butions of current and future dosing costs to the loss function, and avoid either of them to
dominate the criterion.
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Therefore, the “optimal” design parameter (δ1, δ2)opt is defined to be the pair that mini-
mizes the loss function (3.3) over R, that is,
(δ1, δ2)opt = arg min
(δ1,δ2)∈R
L(δ1, δ2).
3.2 Calibration Scenarios Generation
The simulations of design calibration are performed under the linear model (2.1) along with
the variance σ2, which are necessary for generating the responses given doses and predicted
clearance values. It would be natural to obtain estimates of the model coefficients and σ2
by applying least squares fit to the irinorecan data, as in Section 2.1. However, this would
cause the calibration results almost depends on a specific true scenario, and largely weaken
the generality and reliability of RLSEVC.
Thus, in order to avoid the design calibration to depend on some specific cases, we gen-
erate sufficiently many and intensively varying true scenarios, (α, β, γ, σ2), under a Bayesian
framework. Based on the model (2.1), we further assume the following prior distributions
on the model coefficients and variance:






, and, σ2 ∼ IG(η0, η1),
where the initial mean vector b0 is chosen as the theoretical coefficients stated by the PK
model 1.2, b0 = (0, 1,−1)′, the hyper prior variances of model coefficients are assumed to be
common and non-informative as τ 20 = 10
6, and the hyper prior parameters of inverse gamma
(IG) prior distribution are also chosen to be non-informative such that η0 = η1 = 0.1.
Thus, given the design matrix Mn and response vector Yn of the irinotecan data, the joint
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posterior density function can be derived out as follows



































where Mn = (m1, · · · ,mn)′ and mi = (1, xi, zi)′ for i = 1, · · · , n.
Proposition 1 (Marginal Posterior Distributions) Given the joint posterior density























































































































































Based on the marginal posterior densities (3.5), given the irinotecan data and hyper prior
parameters, we at first apply the Gibbs sampling algorithm to generate in total 100,000 pairs
of (α, β, γ, σ2) from these posterior distributions. Actually, in order to ensure the generated
model coefficients satisfying that β > 0, γ ≤ 0, and θ(z) ∈ Ix, the Gibbs sampling is carried
out by keeping only the draws that meet these restrictions until the total number reaches
100,000. At the second, provided that this generated Monte Carlo Markov Chain (MCMC)
converges very quickly, the first 1000 pairs of the draws are burned out. At last, N = 10000
pairs are randomly sampled from the rest draws so as to reduce the auto-correlations among
the MCMC samples downto a acceptably low level.
These final 10000 pairs, denoted as
(
α(j), β(j), γ(j), σ2j
)
for j = 1, · · · , N , will be used as
the true models to generate the response in the simulations of design calibration. In this
way, sufficiently many true scenarios are generated via deeply digging information from the
irinotecan data.
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3.3 Calibrating the Eigenvalue Constraint
In the numerical simulations, in total 166 candidate pairs of (δ1, δ2) are evenly selected within
the area [0, 0.6] × [0, 6] \ 0 × [0, 1]. Specifically, δ1 ranges from 0 to 0.6 with a step size of
0.05, meanwhile δ2 varies from 0 to 6 with a step size of 0.5, only excluding the cases that
δ2 ∈ {0, 0.5, 1} when δ1 = 0. The actual selection area of (δ1, δ2) is chosen not as large as
the theoretical area R, because the eigenvalue constraint would be too restricted to satisfy
if either δ1 or δ2 is too large.
It is worth to mention that, prior to either RLS or RLSEVC, an initial design (size of
n0) is necessary for enabling the least squares estimation of the model (2.1). Since there
are 3 unknown coefficients (α, β, γ) in the model (2.1), at least 3 observations are needed to
initiate the least squares fit. Throughout the simulations of this dissertations, we apply the
BSA formula (1.4) to calculate doses in the initial trial, meanwhile determine its sample size
n0 in a dynamic way. In the numerical simulations, n0 is most often not larger than 5.
Specifically, the sample size of initial trial begins with n0 = 3; if
∣∣M ′n0Mn0∣∣ ≥ δdet, then
the trial is switched from the initial design to RLSEVC; if
∣∣M ′n0Mn0∣∣ < δdet, then one more
subject is recruited into the initial trial (sample size increased to n0+1), and the determinant
is re-evaluated; this procedure will be continued until the determinant exceeds δdet, where
δdet is a pre-selected small threshold and Mn0 is the initial design matrix. This dynamic
sample size determination procedure is to avoid that the singularity of initial design matrix
causes poor initial least squares estimation.
Moreover, another important benefit of the initial design is that, we can utilize the
eigenvalue ratio ρn0 =
log λmax(n0)
λmin(n0)
to estimate the constant C in the eigenvalue constraint
(2.6), where λmax(n0) and λmin(n0) are respectively the maximum and minimum eigenvalues
of M ′n0Mn0 . In this way, the choice of C will be data-driven, and avoid subjective selection.
Algorithm 3 (Calibration of RLSEVC)
For each candidate pair of (δ1, δ2), under the jth true scenario
(
















1. Estimate the dosing function by θ̂
(j)
i (z) =






for any fixed z ∈ Iz;
2. Search for xi+1 = arg min
x∈IX
∣∣x− θ̂(j)i (zi+1)∣∣ subject to the eigenvalue constraint




3. Simulate yi+1 = α
(j) +β(j)xi+1 +γ
(j)zi+1 +εi+1, where εi+1 ∼ N(0, σ2j ), and then update











4. Repeat Step 1 through 3 until i reaches n = 40; at the end of this trial, the dosing cost
D
(j)
n and ISE(j) will be computed.
For each trial, the n subjects are simulated via generating n pairs of (zi, Bi, εi). Specif-
ically, εi’s are iid samples from the univariate normal distribution N(0, σ
2
j ); meanwhile,
(zi, Bi) is generated jointly from a bi-variate normal distribution, whose mean vector and
covariance matrix are respectively estimated by the corresponding sample estimates based
on the irinotecan data (See Table 1.2 in Section 1.4.2).
Throughout the simulations of this dissertation, besides the design calibration, we make
adequate use of the irinotecan data. For example, according to the sample ranges for irinote-
can dose and predicted clearance on log-scale, the ranges of x and z are selected to be
Ix = [5, 8] and Iz = [1.9, 5]. They are set slightly wider than their corresponding confidence
intervals with radius of 6 standard deviations. Particularly, if the dose range is too narrow, it
would help RLS correct the estimated dosing function by truncating it with over-informative
upper and lower limits. Also, a very narrow range of predicted clearance would make the
improvement in MISE between RLS and RLSEVC appear not to be as large as the real dif-
ference. Thus, we select the ranges to be slightly wider than that obtained from irinotecan







































































maintain a comparatively large domain space to highlight the difference between estimated
dosing functions.
Figure 3.1 presents a trade-off trend between MISE and dosing cost across all candidate
pairs of (δ1, δ2). As the magnitude of (δ1, δ2) increases, MISE is gradually improved, while
the dosing cost stays constantly around the lowest level for small pairs and then grows
dramatically since some “inflection” points among intermediate pairs. The trade-off pattern
demonstrates that, spreading design points can improve the least squares estimation, but
would sacrifice certain dosing cost. The optimal pairs of (δ1, δ2) that minimizes the loss
function (3.3) are, respectively, (0.5, 2) for 1 ≤ κ ≤ 5, and (0.3, 3.5) for 5 < κ ≤ 25.
The two ranges of κ respectively represent small and medium-to-large patient horizons of
a future trial. Both the two optimal pairs (highlighted as stars in Figure 3.1) are typical
representatives of these “inflection” points. For a small patient horizon (κ ≤ 5), the dosing
cost of RLSEVC with the optimal pair (0.5, 2) nearly remains the lowest meanwhile its
MISE is improved significantly; for comparatively larger κ, RLSEVC with (0.3, 3.5) trades
mild dosing cost with additional improvement in MISE.
The left two plots of Figure 3.2 show the tendency of dosing cost and MISE depending
on δ1 for each fixed δ2; and, the right two show the δ1-specific dependency of dosing cost
and MISE on δ2. Generally speaking, δ2 has larger impact on the two quantities than δ1
does. For specific δ2 ranging from 0 to 2.5, the dosing cost is not influenced by δ1, while
for δ2 larger than 3, the dosing cost grows quickly as δ1 increases. For every given δ1, the
dosing cost similarly maintains at a low level for δ2 smaller than 2.5, and then dramatically
grows as δ2 increases beyond 2.5. MISE is generally not affected by the variation of δ1, and
decreases significantly as δ2 grows.
Figure 3.3 presents δ1- and δ2- specific dependency of the loss on the other one, given two
representative patient horizons. For κ = 3, the patterns of loss are more similar to those of






















































































































































































of current trial more than that of future patients. For κ = 10, MISE contributes more to
the loss, which leads the corresponding optimal pair to emphasize more on the dosing cost
for future patients. The choice of κ actually relies on the size of a future trial compared to
that of the current, and hence is not possible to explicitly enumerated and evaluated here.
For the loss function, the choice of κ is subtle, as it relies on the size of a future trial. If
a future trial has a small size (1 ≤ κ ≤ 5), then a less restricted constraint (0.5, 2) would be
preferred to emphasize on controlling current dosing cost. If the size of a future trial is much
bigger than the current (5 < κ ≤ 25), then a more restricted constraint (0.3, 3.5) should be
advocated to reduce as much as possible the potential dosing cost paid by future patients.
After all, for the welfare of a large number of future patients, it is worth to sacrifice some
minor welfare of current subjects, as long as which is controlled within an acceptable range.
Consequently, by imposing the eigenvalue constraint on RLS, not only MISE can be
constantly improved as the constraint tightens gradually, but can the dosing cost also remain
at nearly the lowest level for some “inflection” pairs of (δ1, δ2). These “inflection” pairs
of (δ1, δ2) could be options of the optimal choice. Our proposed loss criterion succeeds
in identifying the “optimal” pairs of (δ1, δ2) according to different patient horizons. By
equipping with the “optimal” pairs of (δ1, δ2), RLSEVC is able to improve precision of least
squares estimation significantly, the same time sacrifice little overall dosing cost.
3.4 An Illustrative Trial
In this section, we demonstrate the effects of eigenvalue constraint and coherence restriction
by simulating an illustrative trial. Specifically, for the same 40 subjects (in the sense of
common (zi, Bi, εi), i = 1, · · · , n), we separately simulate a trial (see Figure 3.4) utilizing
each of the BSA, equation, RLS, RLSEVC, RLS-CR and RLSEVC-CR designs, where RLS-




























































































































































The effect of eigenvalue constraint on excluding the asymptotic singularity and improving
precision of least squares estimator can be found by comparing (c) with (d) of Figure 3.4.
Most doses suggested by RLS (c) are stuck at a wrong dosing function that is substantially
biased from the true one, in that the dose sequence converges fast to the wrong target
without receiving any correction from the design. This results in poorly estimated dosing
function (ISE=0.038) at the trial end and large dosing cost (1.821) to the trial. In contrast,
RLSEVC (d) succeeds in forcing design points to slightly spread out along the true dosing
function, as the eigenvalue constraint gradually becomes effective. As a result, RLSEVC
largely corrects the estimated dosing function towards the true one (ISE=0.011) meanwhile
reduce the dosing cost to 0.898. Moreover, by comparing (g) and (h), it can be found that,
except for the subjects of initial trial (n0=4), the RLSEVC trial almost constantly has smaller
dosing biases than the RLS does. It reflects the consistency of dose sequence recommended
by RLSEVC.
Both the BSA (a) and equation (b) based methods fail to provide correct information to
estimate the true dosing function. BSA randomly “guesses” dosage for a subject according to
his/her body surface area, which does not have high association with the predicted clearance.
The equation method could result in large dosing cost, unless the equation is known to be
very close to the true dosing function, which is not realistic in practice. Moreover, the
equation method provides no information for least squares estimation, since the dose column
is co-linear with the other columns in its design matrix.
The effect of coherence restriction on further reducing dosing cost for RLSEVC can be
found by comparing (d) and (f) of Figure 3.4. When the coherence restriction is applied
to RLSEVC, the dosing cost is lowered from 0.898 to 0.795, while the ISE is also reduced
slightly. Comparison between (h) and (i) of Figure 3.4 also shows that more subjects are
benefited with smaller dosing biases in the presence of coherence restriction. It is worth to
mention that, when the asymptotic singularity is present, the coherence restriction cannot
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help RLS with reducing dosing cost or ISE at all (see Figure 3.4 (c) and (e)), which two
trials are exactly the same.
3.5 Design Comparison under Linear Models
In this section, we present a simulation study comparing performance across the competing
designs, BSA, Equation, RLS and RLSEVC under linear models, in terms of the dosing
cost and MISE. By setting (δ1, δ2) = (−∞,−∞), RLS actually becomes a special case of
RLSEVC, where the eigenvalue constraint has no effect. For RLSEVC, (δ1, δ2) is chosen at
the “optimal” pairs, (0.5, 2) and (0.3, 3.5). In addition, to highlight the effect of coherence
restriction, we also particularly include RLS and RLSEVC with and without the coherence
restriction as competing designs in the comparison.
The simulations of design comparison are performed under six representative scenarios
(see Figure 3.5), which are carefully selected to assess the robustness of these designs.
Table 3.1: True Scenarios in Design Comparison under Linear Model




1 0.1236 0.6768 -0.4275 4.3950 0.6316
2 -0.5566 0.6768 -0.4275 5.4000 0.6316
3 1.7500 0.6768 -0.8200 1.9920 1.2116
4 -1.6395 0.6768 0.0000 7.0000 0.0000
5 -0.2182 0.6768 -0.2166 4.9000 0.3200
6 3.0982 0.6768 -1.3536 0.0000 2.0000
aσ=0.2618 is common for all the 6 scenarios.
Among the scenarios, the 1st is typically generated by the Gibbs sampling under the
Bayesian framework as introduced in Section 3.3. It is “regular” in the sense of (α, β, γ)′
satisfying that θ(z) = (t0 − α − γz)/β ∈ Ix for any fixed z ∈ Iz. Based on the 1st scenario,
we create the others by changing either the intercept (t0 − α)/β or slope −γ/β to some
extreme cases, in order to account for extreme dosing functions that are not covered by
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those generated using the irinotecan data under the Bayesian framework. For instance, the
2nd, 3rd and 6th scenarios are “irregular” because their true dosing functions exceed the
dose range Ix on at least one side of the function. Therefore, the true dosing functions of
these scenarios are truncated by upper and lower limits of Ix where they fall out of the
boundaries. Under each scenario, N = 10000 times of simulations are replicated, and the
results are summarized in Table 3.2.
Figure 3.5: True Dosing Functions of Design Comparison under Linear Model
In table (3.2), the average of dosing cost (3.1) and MISE (3.2) over all simulated trials
are respectively summarized for each design under each scenario, where the loss function
(3.3) is computed with κ = 10. All these numbers are the smaller the better, while MISE is
multiplied by 100 to save displaying digits and make the numbers appear reader-friendly.



































































































































































































































































































































































































































































































































































































































































































































































worse than RLS and RLSEVC, in terms of both the dosing cost and MISE. Their performance
largely depend on the true scenario, because their dosing costs are out of control at all
scenarios other than the 1st. The BSA algorithm fails to provide useful design information
to estimate the dosing function and thus result in the worst MISE across all scenarios; the
equation method is not able to estimate dosing function using least squares, hence its MISE
is not available all the time. In clinical practices, where the true dosing function is never
known, applying such unstable designs as the BSA or equation algorithm would expose
patients to severe safety issues.
In contrast, RLS and RLSEVC improve MISE significantly meanwhile control the dosing
cost robustly, even under the extreme scenarios. Although the performance of RLS seems
acceptable in general, due to failing to exclude the asymptotic singularity, its MISE is con-
stantly worse than that of RLSEVC. Because the asymptotic singularity is a phenomenon
that does not happen frequently, the improvement in MISE from RLS to RLSEVC does not
seem as significant as that from BSA to them. However, it is the ability of overcoming the
asymptotic singularity that gives RLSEVC the reliability and safety that RLS is in short of,
because “exceptions” are not acceptable in real practices.
For regular scenarios (the 1st, 4th and 5th), the eigenvalue constraint helps RLSEVC
significantly improve MISE over RLS, for instance 24 percent reduction (from 1.16 to 0.88)
in MISE at Scenario 1; moreover, when (δ1, δ2)opt = (0.5, 2), RLSEVC can also reduce the
dosing cost compared to RLS. For irregular scenarios (the 2nd, 3rd and 6th), the truncation
by the dose range Ix largely helps RLS improve estimation accuracy, and hence result in
similar MISE with RLSEVC at the 2nd and 6th scenarios, while RLSEVC still largely reduces
MISE compared to RLS at the 3rd scenario. However, RLSEVC constantly achieves smaller
dosing costs than RLS does at these irregular cases. The trade-off between the overall dosing
cost and MISE is still clear for RLSEVC across all scenarios. Thus, the choice between the
pairs of (δ1, δ2)opt is subtle indeed, and should depend on the size of a future trial as we
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discussed in Section 3.3.
By respectively comparing RLS-CR and RLSEVC-CR with those without the coherence
restriction, we can find that the coherence restriction further lowers the dosing cost effec-
tively, with maintain the same level of MISE (for instance scenario 1) or even gaining mild
improvement in MISE (for instance scenario 4 and 5). Another advantage of the coherence
restriction is that, it can also shrink the searching range for the dose that minimizes the loss
function, and thus substantially save computation time for implementing RLSEVC.
At last, the dosing cost per each subject across an RLSEVC trial is also recorded, in order
to investigate the overall trend in which the individual dosing cost varies as a trial proceeds.




for i = 1, · · · , n. In Figure
3.6, across RLS and RLSEVC with coherence restriction as well as the BSA and equation
designs, the average individual dosing cost over all simulated trials is plotted against the
subject sequence number under all the 6 scenarios.
From Figure 3.6, it can be clearly told that the individual dosing costs of either BSA
or equation algorithm do not vary with the trial process at all. So, in these two designs,
the “costs” paid by subjects enter a trial earlier are not used to benefit the later subjects,
which is indeed a waste of valuable information resources. Moreover, for BSA and equation
algorithms, the dependence of individual dosing cost on the true scenario is obvious. For
instance, the cost can be fairly small when using the equation algorithm under Scenario 1,
because where the true dosing function is close to that specified by the equation algorithm
(1.3); but, the cost becomes very large for the equation algorithm under Scenario 4, as its
fixed dosing formula (1.3) now is biased away from the true dosing function too much. As
mentioned previously, the true scenario is never known in reality, hence the practice using
such unreliable dosing algorithms is highly risky for patients.
For RLS and RLSEVC, a clear pattern that the individual dosing cost increases slightly
























































approach zero in the later half trial is shown under all scenarios in Figure 3.6. This pattern
not only indicates that the costs paid by early subjects are well utilized to optimizing dose
assignments to later subjects, but also demonstrates that the dose sequence recommended
by RLSEVC is consistent. The reason why RLS almost behaves as well as RLSEVC does
in terms of the individual dosing cost is still that, the asymptotic singularity does not occur
frequently and so leads to slight difference on the overall average costs. Since the initial
design is based on the BSA formula, the cost of either RLS or RLSEVC is always the same
as that of BSA algorithm for the first 3 subjects. If the starting points are close to the
true dosing function, such as Scenario 1, the eigenvalue constraint would force the upcoming
several design points to spread out certainly, which explains the increment in dosing cost at
beginning; upon the design collects sufficient information to ensure estimation precision, the
costs quickly decrease to zero in later half trial. In other words, the first several subjects
would pay costs for the benefits of most later subjects among an RLSEVC trial.
Consequently, we strongly advocate the use of RLSEVC with coherence restriction, since
it not only controls the dosing cost well, estimates the dosing function precisely, but is also





4.1 Semiparametric Dose-Response Model
The most fundamental assumption that the repeated least squares procedure relies on is
the linear relationship (2.1) between the AUC, dose and predicted clearance on log-scale.
However, in reality, the true dose-response model is always unknown, and thus the linear
model assumption could be violated and the dosing methods relying on such a specific
assumption is risky. When the true underlying model is nonlinear, the subjects enrolled in
the trial could be exposed to systematic dosing errors, and also future patients could be
exposed to the risk of a poorly estimated dosing function. Therefore, a robust dose-finding
design that can adapt for more general dose-response model settings than the linear model
(2.1) is in need to develop. In this chapter, we propose a novel semiparametric adaptive
design, which can not only determine doses adjusted for subjects’ predicted clearance, but
could also adapt for an unknown dose-response link function under a semiparametric model.
To generalize the linear model (2.1), we suppose that the relationship between the loga-
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rithm of AUC, dose and predicted clearance follows a nonlinear model as follows:
y = g(α + βx+ γz) + ε, β > 0, γ ≤ 0, (4.1)
where y, x and z still respectively denote the AUC, continuous dose and predicted clearance
on log-scale; g(s) is an unknown increasing link function; and, ε is a normally distributed
random error with zero mean and finite variance σ2.
Actually, without loss of generality, we can further assume that α = 0 and β = 1,
because, by defining a new link g∗(s) = g(α + βs), the mean structure of Model (4.1)







without changing any condition on the
link function. Therefore, for identifiability, as long as the link is unknown, we assume the
following nonlinear model in the rest of this dissertation:
y = g(x+ φz) + ε, φ ≤ 0. (4.2)
Suppose that the true direction parameter is φ0, and the parameter ranges is a bounded
closed interval Iφ ⊂ (−∞, 0]. Also, in the rest of this chapter, we denote the “index” as
s = x+ φz.
According to the conditions on the link, s should take values within IS, where IS is the
compact domain of the link function g(.).
By assuming the single-index model (4.2), the number of unknown parameters is reduced
by “absorbing” the intercept α and dose slope β into the link function. And, more impor-
tantly, since x is a stochastic regressor while z is a non-random covariate, the model (4.2)
bypasses the estimation for the dose slope β, and so avoids the need for special control on
the dose convergence rate as the eigenvalue constraint (2.6) does. However, this does not
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mean that the estimation for model (4.2) would be easier to conduct, as it actually transfers
the difficulty in estimation of β to that of the link function g(.). This point will be further
discussed in Section 4.5.
4.2 Isotonic Semiparametric Least Squares Estimation
The model (4.1) and (4.2) are single-index models, which naturally extend the linear models,
meanwhile overcomes the “curse of dimensionality” and lack of interpretability by linearly
projecting all covariates into one single predictor. Over the past decades, the estimation
methods for single-index models have been well studied in the community of semiparametric
regression models. A brief review of these methods can be found in Chapter 6 of Hardle et al.
[2004]. This section will introduce a two-stage iterative semiparametric estimation method
for the single-index models, which will be recursively applied to estimate the dosing function
in our proposed semiparametric adaptive design.
One commonly used approach to estimate the single-index models is the semiparametric
least squares (SLS) method [Ichimura, 1993]. Generally speaking, SLS estimates φ by





yk − g(xk + φzk)
)2
,
where the unknown link function g(.) is viewed as a nuisance parameter and estimated by a
consistent nonparametric smoother point-wisely.
Weisberg and Welsh [1994] independently propose a pseudo maximum likelihood version
of SLS method under the generalized linear model setting with a missing link. Their iterative
approach at first estimates the direction parameter φ0 using the canonical link, then estimates
the link by a kernel smoother given the estimated direction parameter obtained from the
first step, and then re-estimates the direction parameter via the pseudo maximum likelihood
estimation with plugged-in kernel estimators. They solve a pseudo score equation by using
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the Newton-Raphson algorithm, and iterate between the second and third steps until certain
convergence criterion is met, so as to obtain the final estimate of φ0.
Under the assumption that the response distribution is from a two-parameter exponential
family, the score equation of maximum likelihood is the same as the normal equation of least
squares. Thus, under a generalized linear model setting, the iterative approach by Weisberg
and Welsh [1994] is essentially the same as SLS in terms of the estimation of direction
parameter φ0. For our proposed semiparametric sequential design, the iterative estimation
approach by Weisberg and Welsh [1994] has to be applied with several modifications to
estimate the single-index model (4.2).
When applying SLS to estimate the model (4.2), besides the unknown link g(.), the
first order derivative g′(.) is also involved in the pseudo score equation and thus needs
to be estimated as well. Weisberg and Welsh [1994] use two separate kernel smoothers
to estimate g(.) and g′(.) respectively, where the kernel estimate of g′(.) also contains the
plugged-in kernel estimate of g(.). In the early 1990s when Weisberg and Welsh [1994]
proposed this method, it is also the period when the nonparametric regression methods are
developed rapidly, for instance the local polynomial regression models. As introduced in
Chapter 2 and 3 of Fan and Gijbels [1996], the local polynomial estimator not only keeps
all advantages of the classic kernel smoothers, but also owns extra benefits over them, for
example, simultaneously estimating the regression function and its derivatives, adapting to
both fixed and random designs, and more accurate estimation on the boundary. Considering
of these desirable properties, we thus modify the SLS [Weisberg and Welsh, 1994] by replacing
the kernel estimators with the local linear estimator wherever the estimation for the link g(.)
and its first order derivative g′(.) is in need.
Moreover, another major modification that we make to the nonparametric regression part
of SLS [Weisberg and Welsh, 1994] is to incorporate the monotonicity of the unknown link
function into the estimation procedure. The nonparametric regression methods, such as the
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kernel smoothing or local polynomial fit, only make use of the smoothness of the link function,
but do not utilize the monotonicity at all, and thus cannot guarantee a monotone estimate.
However, for reasonable interpretation of the dose-response model (4.2), the estimated link
has to be increasing in the index s = x + φz. Therefore, we apply an isotonisation step
[Mammen, 1991, Mukerjee, 1988] to the responses corresponding to the ordered indexes
prior to the local linear regression, so as to ensure the resultant link function estimate is
monotone. In brief, the first step is using the isotonic regression [Mukerjee, 1988] to obtain
the isotonized version of yi onto the ordered indexes; then, the second step is applying the
local linear fit to the pairs of isotonized responses and ordered indexes.
Algorithm 4 (Isotonic Semiparametic Least Squares Estimation) The isotonic semi-
parametic least squares (ISLS) estimation that we propose to sequentially estimate the model
(4.2) is summarized as follows. Given (yi, xi, zi), i = 1, · · · , n,
1. Assuming the canonical (identity) link at first, the model (4.1) is reduced to the linear
model (2.1), so it is natural to apply least squares estimation to obtain (α̂n, β̂n, γ̂n)
′.
Now, the model (4.2) is actually E(y|x, z) = g(x+φz) with a linear link g(s) = α+βs
and φ = γ/β. Then, an initial value of φ0 can be estimated by φ̂0 = γ̂n/β̂n, and the
initial index values can be computed as ŝ
(0)
k = xk + φ̂0zk, for k = 1, · · · , n.
2. For the jth iteration (j ≥ 0), we first sort the index values to obtain the ordered indexes
ŝ
(j)
(k) = xk+ φ̂jzk, k = 1, · · · , n, along with y(k) being the response corresponding to ŝ
(j)
(k).








L2 − L1 + 1
, for k = 1, · · · , n. (4.3)
















, and obtain the point-wise estimates
of link function and its first order derivative at ŝ
(j)
(k) for k = 1, · · · , n. Particularly, for
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are respectively the design matrix and diagonal kernel weight matrix of local linear
regression at the point s, Y ∗n = (y
∗
1, · · · , y∗n)′ is the isotonized response vector, the
kernel function K(.) is a symmetric light-tail probability density function and Kh(.) =
1
h
K(./h), and h is a bandwidth controlling the size of the local neighborhood and




. For simplicity, we denote Vn(s) =




n in the rest of this chapter.

















where sk(φ) = xk + φzk for k = 1, · · · , n, and the local linear estimators ĝn(.) and
ĝ′n(.) are plugged in to substitute the unknown link and its first order derivative. The
Newton-Raphson algorithm is applied to solve the equation (4.5) as follows:




































(∣∣∣Vn(ŝ(j)(k))∣∣∣), z(k) is ordered up to ŝ(j)(k) for k =
1, · · · , n, and
∣∣∣Vn(ŝ(j)(k))∣∣∣ is the determinant of the matrix. The function Ja(t) is a
smooth version of the indicator function that targets at stabilizing the local linear
estimator at points where
∣∣∣Vn(ŝ(j)(k))∣∣∣ is close to zero. According to Weisberg and
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, for − 1 ≤ x ≤ 1,
where the tuning constant a is required to decrease to 0 more slowly than the bandwidth




. Such smoothing modification is common
and necessary for nonparametric regression estimation, as a small determinant on the
denominator of (4.4) would largely bias the estimator. The smoothed indicator function
actually allows only those points at which the local linear estimation is stable to fully
contribute to the correction term updated in the iterative algorithm.
5. Repeat Step 2 through 4 until some convergence criterion on φ̂ is satisfied. In this
research, the Cauchy convergence criterion is applied. Specifically, if there exists a
fixed number N∗ such that
∣∣φ̂j − φ̂j+1∣∣ < ξ, for j = N∗, · · · , N∗ +m, (4.7)
where the threshold ξ and step-length m are pre-selected, then the iterative estimation
procedure is considered convergent.
Based on the iterative estimation approach ISLS, we develop a novel individualized dose-
finding design, the semiparametric link-adapted recursion (SLAR), which can adapt for the
unknown link function under the semiparametric model (4.2).
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4.3 Semiparametric Link-Adapted Recursion Design
The primary goal is still looking for a sequential design such that E(y|x, z) can reach the
target level t0. Under the single-index model (4.2), the trial objective then becomes the
estimation of the following target dosing function:
θ(z) = s0 − φ0z, for any given z ∈ Iz, (4.8)
where s0 = g
−1(t0). Intuitively, the aforementioned conditions on the link function g(.) is to
guarantee the invertibility of g(.) at t0, in other words, the existence and uniqueness of s0.
In brief, the essential idea of the semiparametric link-adapted recursion (SLAR) design is,
iteratively estimating s0 and φ via using ISLS to the current i observations, then assigning an
estimated dose θ̂i(zi+1) = ŝ0i−φ̂izi+1 to the (i+1)th subject, and repeating this procedure for
next subjects until a pre-specified sample size is reached. This sequential procedure involves
recursive estimation of the unknown link function g(.) and the direction parameter φ0 as the
trial proceeds. In order to ensure a consistent dose sequence, it is of core interests to obtain
precise estimates of not only the direction parameter φ0 but also the inverse link at t0, that
is, s0 = g
−1(t0).
The semiparametric link-adapted recursion (SLAR) is a two-stage design: the first stage
with a sample size n1 (n0 < n1 ≤ 40) applies the repeated least squares procedure, while the
second stage is actually the proposed SLAR design. One reason for the necessity of the first
stage is that, the nonparametric regression fitting involved in ISLS typically requires certain
amounts of data points to guarantee the precision and reliability of nonparametric estimation.
Also, another reason is that, the first stage can lead to an data-driven initial estimate for
the direction parameter φ0, which is necessary to launch the iterative estimation of the link
and φ0. Specifically, the first step of ISLS postulates the canonical link, which is the identity
link under the normal distribution assumption. The model (4.1) with the identity link is
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reduced to the linear model (2.1), and thus, the repeated least squares procedure becomes
a natural choice for the design. In fact, the choice of the switching point (n1) is crucial
for SLAR, because, intuitively, an early switch would cause comparatively less accurate
nonparametric estimates due to the small sample size, and further affect the estimation
precision of ISLS. The calibration of selecting n1 for SLAR will be discussed in subsequent
numerical simulations.
At the end of the first stage, the least squares fit to (yi, xi, zi), i = 1, · · · , n1, leads to the
estimates (α̂n1 , β̂n1 , γ̂n1)
′, which is used to trigger the second stage. Specifically, the initial
estimate of φ0 suggested by the first stage is
φ̃n1 = γ̂n1/β̂n1 , (4.9)
which is truncated from up by 0, so as to ensure that AUC decreases in the predicted clearance
given the increasing link function. Then, the initial “index” values can be calculated as
s̃
(n1)
k = xk + φ̃n1zk for k = 1, · · · , n1, which are used to initiate the local linear regression for
the link function at the beginning of the second stage.
Algorithm 5 (SLAR)
For the (i + 1)th subject, i = n1, · · · , n, given {(yk, xk, zk)}ik=1 and φ̂i−1, where, especially,
the initial estimate of φ at the n1 step is φ̃n1 (4.9),
1. First of all, the initial indexes at the (i + 1)th step are computed as s̃
(i)
k = xk + φ̃izk,
k = 1, · · · , i, where φ̃i = φ̂i−1. Then, we conduct the isotonisation step (4.3) to
















2. At the second, we perform the following iterative ISLS procedure.




































by (4.4) for k = 1, · · · , i.
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ii) Update the estimate of φ0 by the root to the pseudo score equation (4.5) that is
solved by the Newton-Raphson algorithm (4.6):





































iii) Update the indexes with φ̂i (4.10), such that
ŝ
(i)
k = xk + φ̂izk for k = 1, · · · , i, (4.11)
and then iterate between Step (2.i) and (2.ii) until the Cauchy criterion (4.7) on
φ̂i is satisfied.
Upon the above iteration converges, the estimates of φ0, indexes and link function at
















for k = 1, · · · , i.











, we search for the root to t0 = ĝi(s) by using a
numerical root-searching algorithm. The choice on the algorithm is determined dynam-



























, a Bisection algorithm will be applied;






, an Uphill searching algorithm will be applied;






, a Downhill searching algorithm will be applied.
As a result, the root ŝ0i to t0 = ĝi(s) is the estimate of s0 = g
−1(t0) at step i.
4. Given ŝ0i and φ̂i, the dosing function is estimated by
θ̂i(z) = ŝ0i − φ̂iz, for any fixed z ∈ Iz. (4.12)
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5. Once yi+1 is observed, the trial proceeds to the next subject and repeats Step 1 through
4. The sequential procedure continues until the sample size reaches n. At the trial’s
end, the estimated dosing function θ̂n+1(z) will be recommended to future patients.
The crucial steps of implementing SLAR is the Newton-Raphson and root-searching
algorithms, as they respectively estimate the slope and intercept of the true dosing function


























, then we respectively set the starting
lower and upper limits of the search as s = ŝ
(i)
(1) and s̄ = ŝ
(i)
(i).









, k = 1, · · · , i, so as to obtain ĝi(stj).
2. If ĝi(stj) > t0, then we update s̄ with stj and repeat Step 1; if ĝi(stj) < t0, then we
update s with stj and repeat Step 1.
3. Iterate Step 1 through 2 until ĝi(stj) = t0 for some stj. At last, the finally updated stj
is the root to t0 = ĝi(s), that is ŝ0i.























. The former can be guaranteed
by the isotonisation step prior to the local linear regression, but the latter cannot be ensured
by the estimation procedure. Actually, if the initial estimate φ̂n1 is substantially biased away
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, a Downhill searching algorithm should be used to replace the






, an Uphill searching algorithm should be used instead.
In brief, the Downhill algorithm is, to search with a step-size for such a point st that ĝi(st)
the first time downcrosses the target t0, and then switch to the Bisection algorithm by setting
st as the initial lower limit s; and, likewise for the Uphill searching algorithm.
Motivated by the need for an individualized dosing algorithm that adapts for an unknown
link, SLAR is proposed to compete with the repeated least squares procedure. Under a
semiparametric model, SLAR targets at suggesting more accurate doses within a trial and
leading to more precisely estimated dosing function at a trial’s end than RLSEVC does. In
fact, as the second stage, SLAR relies on the performance of RLSEVC in the first stage.
The repeated least squares procedure, especially RLSEVC, plays an important role in
providing a reliable initial estimate φ̃n1 (4.9) to launch the second stage of SLAR. As a
crucial part of SLAR algorithm, the Newton-Raphson algorithm results in the estimate of
φ0, but its performance somehow depends on the initial value φ̃n1 . A very biased initial
value could cause that, the resultant estimates ŝ0i and φ̂i are also biased away from the
true values, or even the Newton-Raphson algorithm does not converge at all. If φ̃n1 was too
far away from the true value φ0, then the local linear fit would take place at a place far
away from the true location, and thus lead the solution of t0 = ĝi(s) to deviate from the
true value s0 = g
−1(t0). The Bisection algorithm is fast-converging and stable though, it
cannot correct any information regarding the location of fitting the nonparametric curve. As
a result, the dosing function would be poorly estimated. The use of repeated least squares
procedure, especially RLSEVC, in the first stage can largely avoid the occurrence of a very
biased φ̃n1 . On one hand, due to wrong model assumption, the resultant estimates of φ0 and
s0 by RLSEVC may not be accurate enough, and so need further improvement by SLAR;
however, on the other hand, they are reliable enough to an ideal initial value for the second
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stage of SLAR.
Moreover, besides the Newton-Raphson algorithm, another important influential part for
the performance of SLAR is the local linear fit. Due to the iterative estimation manner of
φ0 and g(.), the local linear fit not only directly determines the search for s0, but also has
influence on estimating φ0 through the correction term in (4.10). An unstable local linear
estimates of g(.) and g′(.) would attribute to an unstable correction term (especially for
Âi) in updating φ̂i, which could cause the iterative algorithm not to converge. To stabilize
the local linear estimates, we calibrate the choice of the switching point n1, which will be
discussed in subsequent section of simulations, and particularly use a dynamic way to select
the bandwidth.
Specifically, the rate of bandwidth is chosen at the optimal rate O(n−1/5) (see Comment










so as to ensure certain amount of observations in a local neighborhood. Moreover, if some
“isolated indexes” are detected, the bandwidth would be enlarged enough so that at least
two data points are contained in each isolated index’s local neighborhood. The existence
of these isolated indexes is due to the small sample size and the tendency that the indexes
concentrate around s0. The estimated indexes at stage i are actually
ŝ
(i)
k = xk + φ̂izk = ŝ0,k−1 + (φ̂i − φ̂k−1)zk, for k = 1, · · · , i. (4.15)
As long as φ̂i and ŝ0i are consistent for φ0 and s0 respectively, the index sequence {ŝ(i)k }
should approach s0 regardless the covariate values zk, especially for those in late trial. Since
our major interest regarding the nonparametric regression is the estimation at the point
(s0, t0), rather than the entire curve, the aforementioned phenomenon can benefit the search
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for s0 by making most data surround the fitting location of interest. However, it also has
a side effect that several early indexes would be “isolated” from the majority, in the sense
that their local neighborhoods defined by the bandwidth (4.14) have no data points other
than themselves. The local linear fitting at such isolated indexes could result in an unstable
correction term in updating φ̂i, because the Â
−1
i could be very close to zero. Our proposed
dynamic bandwidth selection succeeds in overcoming this issue. In fact, when RLSEVC is
utilized as the first stage, the effect of eigenvalue constraint in spreading design points also
can certainly avoid the indexes to concentrate around s0 too rapidly.
4.4 Applications of Semiparametric Link-Adapted Re-
cursion
4.4.1 Fitting Semiparametric Models to Irinotecan Data
In the numerical evaluation of SLAR, the criteria measuring the performance of designs are
still the same as those defined in Section 3.1, that is, the dosing cost (3.1) and ISE (3.2).
The first step of numerical simulations would be to select suitable true models that will be
used to generate the responses. So, it is of interest to fit certain single-index models to the
irinotecan data, so as to obtain the “suggestions” on the model from the data.
Looking into the specific single-index model (4.2), the parameter φ determines the “loca-
tion” where the nonlinear regression between the response y and index s = x+ φz happens.
Without prior knowledge on clinical meaning of the index s, we should not suppose any
specific location range of the index, but can dig that information out from the irinotecan
data. The method that we use to find φ0 is similar to maximizing a nonparametric profile
likelihood on φ.
Given the irinotecan data {(yi, xi, zi)}ni=1 and any fixed φ ≤ 0, the indexes si = xi + φzi
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for i = 1, · · · , n, are computed at first; then, a nonparametric kernel smoothing between
{yi} and {si} is performed to obtain the kernel estimates {g̃(si)} point-wisely; at last, the










Figure 4.1: Profile of Residual Square Sums from Kernel Smoothing
By letting φ vary through at sufficiently many values within (−∞, 0] and correspondingly
performing the kernel regression at each fixed φ, a profile of RSS(φ) can be obtained then,
as shown in Figure 4.1. The optimal φ suggested by the irinotecan data is the one that
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minimizes RSS(φ) over φ ∈ (−∞, 0]. As shown by Figure 4.1, there is a unique minimizer
of RSS(φ), which is φopt = −1.25. We will set the true parameter as φ0 = −1.25 in the
subsequent numerical simulations of this dissertation.
Given φ0 = −1.25, we fit several specific nonlinear link functions to the data {(yi, si)}ni=1,
where now si = xi + φ0zi. The first one is a commonly used model in the pharmacokinetics
and pharmacodynamics (PKPD) theory, the Emax model [Kirby et al., 2011]. The Emax
models usually postulate the following nonlinear association between a response y and a
predictor D, which could be the dosage or any clinically important biomarker.






where E0, Emax, ED50 and ζ are unknown parameters and random noise ε is assumed to
normally distributed with zero mean and finite variance σ2. Particularly, E0 represents
the minimum possible response corresponding to D=0, E0 + Emax represents the maximum
possible response as D increases to +∞, ED50 is the predictor level that produces half of the
Emax effect and actually controls the location of the curve, and ζ is the slope and controls
the steepness of the curve. All the parameters are positive, so that the mean response would
be increasing in the predictor. A typical Emax curve shape can found in Figure 4.2 (b).
If we suppose the true link function g(.) is an Emax link, such that




, for s ∈ IS, (4.17)
then, by applying the nonlinear least squares fit to the data {(yi, si)}ni=1, the estimated model
(p-values) is obtained as Ê0 = 2.92 (p < 0.0001), Êmax = 0.36 (p = 0.3), Ês50 = 2.28 (p
< 0.0001), ζ̂ = 19.28 (p = 0.57) and σ̂ = 0.2555, with a significant model (Wald test p <
0.0001). The estimated Emax link is shown in Figure 4.2 (b). Its model fitting (see Figure























as the data themselves display no significant linear or nonlinear pattern because of its small
range and limited sample size.
Besides the Emax link, we also use the nonlinear least squares to fit a power link function,
such that
g(s) = ψ0 + ψ1(s− ψ3)ψ2 , for s ∈ IS. (4.18)
The estimates are ψ̂0 = 2.74 (p < 0.0001), ψ̂1 = 0.06 (p = 0.85), ψ̂2 = 2.71 (p = 0.62) and
σ̂ = 0.2533, with a significant model (Wald test p < 0.0001), when the location φ3 is fixed
at 0.35 (otherwise the Newton-Raphson algorithm in the nonlinear least squares fit does not
converge). The power link model appears to fit the data slightly better (R2 = 0.135) than
the Emax link does (see Figure 4.2 (f)), however, due to the non-patterned data, it still does
not display persuasive evidence that the power link fits the data perfectly.
Figure 4.3: Nonlinear Links used in Simulations
However, the choice of true models used to generating responses in simulations should not
depend on specific data sets completely, otherwise the simulation results would also depend
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on the particular data and lose generality. Therefore, in the subsequent simulations for
evaluating the performance of SLAR, we use the Emax and power links, but with some minor
modifications on the parameter estimates to make the nonlinear shape of the curves much
clearer. Specifically, given φ0 = −1.25, the parameters of Emax link are selected respectively
as E0 = 2.6, Emax = 1.05, Es50 = 2.4, ζ = 20 and σ = 0.2555; meanwhile, the parameters
of power link are respectively ψ0 = 2.6, ψ1 = 0.035, ψ2 = 4, φ3 = 0.35 and σ = 0.2533 (see
Figure 4.3). The parameters regarding the mean structures are modified slightly to highlight
their nonlinear shape, provided that the data do not show any significant pattern. While
the location parameter φ0 and the dispersion σ are kept the same as those obtained from
the irinotecan data, so as to maintain those information dug out from the data.
4.4.2 An Illustrative Trial
In this section, we illustrate the SLAR’s advantage in improving the estimation precision
over RLSEVC by simulating an illustrative trial. Similar to the sample trial in Section 3.4,
we simulate a trial of n = 40 subjects by utilizing RLSEVC connected with SLAR at its end
(n1 = 40), where (δ1, δ2) = (0.3, 3.5) for RLSEVC and the coherence restriction is applied as
a default. The true model to generate responses is the Emax link model (4.17) mentioned
at the end of Section 4.4.1.
The left plot in Figure 4.4 presents the true mean response function against the index,
along with the two estimated mean curves by RLSEVC and SLAR respectively. The focus
of curve estimation is indeed at the point (s0, t0), where the curve crosses the target mean
level of the response. The curve estimated by RLSEVC crosses t0 at ŝ0n = 2.71. At the
end of the RLSEVC trial, the additional step of SLAR improves the estimate to ŝ0n = 2.41,
which is closer to the true value s0 = 2.39 for this example. This improvement in estimating
s0 is mainly sourced from the improvement in estimating φ0 by SLAR over RLSEVC. The


































































































































































It largely corrects the location where the estimated curve crosses the target level from that
(φ̂n = −1.14) obtained by RLSEVC. Due to the comparatively large variation of the noises
and the tendency that the indexes concentrate around s0, the shape of mean response curve
estimated by SLAR is not very close to the true emax curve. But, the shape does not impact
the estimation of s0 indeed, as long as the estimated curve crosses the target level t0 close to
the correct location, because which actually determines the intercept s0 of the true dosing
function (4.8).
The plot in the middle of Figure 4.4 displays the true dosing function and estimated
dosing functions by RLSEVC and SLAR, respectively. Although the estimated function
by RLSEVC is already close (ISE= 0.004) to the true one, SLAR further improves the
estimation (ISE= 0.0004) so that the estimated function by SLAR is nearly identical to the
true function. In addition, the right plot shows the sequential dosing biases of the simulated
trial, which does no relation with SLAR, but indicates that the dosing accuracy of RLSEVC
is actually acceptable even under a nonlinear model, in other words, RLSEVC is acceptably
robust against link misspecification.
From this illustration, it can be found that the dosing cost and MISE of RLSEVC are
actually acceptable under model misspecification, however, the semiparametric link-adapted
recursion can even further improve the estimation precision of the model parameters and
dosing function. In the subsequent section, a large-scale simulation study will further confirm
this point.
4.4.3 Design Comparison under Semiparametric Models
In this section, a simulation study is presented to comprehensively compare the performance
of the two-stage SLAR with the repeat least squares procedure under both the linear and
semiparametric models. The goals of this simulation study include: demonstrating the
advantage of SLAR over the repeated least squares procedure under semiparametric models,
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investigating the impact of the switching point n1 on the performance of SLAR and attempt
to identify out a recommended switching point, and investigating the robustness of the
repeated least squares procedure to link misspecification. The criteria (dosing cost and ISE)
assessing the design’s performance are still the same as those defined in Section 3.1.
In the simulations, the first stage design uses both RLS and RLSEVC for comparison,
where (δ1, δ2) is chosen at (0.5, 2) and (0.3, 3.5). Due to the benefits of coherence restriction
demonstrated in all the previous simulations, it will be applied to RLS and RLSEVC as a
default. For the second stage of SLAR, the switching point n1 is respectively selected at 25,
30, 35 and 40. When n1 = 40, the first stage design takes charge of dose assignments for
the entire trial, while the second stage SLAR will be used to only re-estimate the dosing
function at the end. In the comparison, RLS and RLSEVC will be regarded as special cases
of the two-stage SLAR, where there is no second stage.
The comparison across designs and different choices of n1 is conducted under four repre-
sentative models, among which two are the linear models (the 1st and 6th scenario in Table
3.1 used in the simulation studies in Section 3.5), and the other two are respectively the
Emax link and power link models introduced at the end of Section 4.4.1. The reason for
choosing the 1st and 6th scenarios as the linear models is that they typically represent the
regular and irregular linear scenarios, which are discussed at the beginning of Section 3.5.
Under each model, in total N = 5000 trials with sample size n = 40 will be simulated using
each design. The simulation results under linear and semiparametric models are respectively
summarized by Table 4.1 and 4.2.
As shown by Table 4.1, the general pattern among the results under the linear models is
that, the two-stage SLAR performs close to but slightly worse than the one-stage RLSEVC
in terms of MISE, but remains nearly the same level of dosing costs. Although the estimation
precision of SLAR is slightly worse than RLSEVC under the linear models, the difference in





























































































































































































































































































































































































model, the parametric methods should be more precise than the semiparametric approaches,
especially considering of the small sample size under our phase I trial settings. For example,
under the 1st linear scenario, when the two-stage design is RLSEVC ((δ1, δ2) = (0.5, 2))
connected with SLAR at n1 = 40, it produces an MISE (0.901) that is only 4.2% larger than
the MISE (0.865) of the corresponding RLSEVC.
Specifically, under the 1st linear scenario, RLSEVC with (δ1, δ2) = (0.5, 2) is the best
design in the sense of minimizing the loss criterion; for the two-stage SLAR, as the switching
point n1 decreases from 40 to 25, MISE gradually increases, while the dosing cost remains
the same in general or even slowly decreases for RLSEVC with (δ1, δ2) = (0.3, 3.5). The
decreasing pattern of MISE on n1 indicates that, for SLAR, the switching point n1 should
not be too small (less than 30), otherwise, there would not be enough observations to ensure
the precision of local linear regression and thus the precision of estimated dosing function.
In addition, it is also obvious that the estimation precision of SLAR relies on the first stage
design. For each fixed n1, by comparing MISE across the three different first stage designs, it
can be found that the more precisely the first stage design performs in estimation, the more
precise the estimated dosing function suggested by SLAR will be. Among the three, RLS
would be the worst choice for the first stage, while RLSEVC with (δ1, δ2) = (0.5, 2) would
be a better choice due to its smaller loss. The reason is because of the effect of eigenvalue
constraint in spreading design points. The estimated indexes tend to concentrate around
s0, so the eigenvalue constraint can also help SLAR improve local linear fitting by slowing
down the speed in which the indexes approach s0. It would interesting to notice that, when
using RLS as the first stage design and switching to SLAR at the end (n1 = 40), the MISE
produced is even much larger than those corresponding to smaller n1. The reason is because
the effect of asymptotic singularity accumulated towards the end of some problematic trials
and results in poor least squares estimation. When switching to SLAR at the end RLS,
SLAR cannot correct the poor estimation but could produce even worse estimation due to
81
the poor initial values. It again demonstrates that the performance of SLAR relies on the
first stage design, and RLSEVC is a much reliable choice than RLS.
Under the 6th linear scenario, the similar patterns among dosing cost and MISE can be
found, only except for that the difference across different n1 is smaller due to the trunca-
tion on the estimated dosing function. The simulation results under the two linear models
demonstrate that the two-stage SLAR with RLSEVC as the first stage does not sacrifice
much precision to gain the robustness and generality. Considering of the small sample size
at these cases, the semiparametric estimation is fairly accurate enough compared to the
parametric methods.
As in Table 4.2, the simulation results under the semiparametric models show a general
pattern that, the two-stage SLAR performs much better than the one-stage repeated least
squares procedure in terms of MISE, meanwhile takes even smaller dosing costs. As n1
decreases from 40 to 25, MISE of the two-stage SLAR reduces at first from 40 to 35, and
then turns to increases gradually since 35 downwards to 25; while the dosing cost of the
two-stage SLAR at n1 = 40 reduces largely compared to the corresponding RLSEVC, and
then further decreases slightly as n1 decreases. For instance, under the Emax link model,
when switching from RLSEVC ((δ1, δ2) = (0.5, 2)) to SLAR at n1 = 35, the resultant MISE
(0.538) gets a 39.2% reduction from the MISE (0.885) of RLSEVC; also for this example,
the dosing cost (4.796) and loss (6.948) of the two-stage SLAR are respectively 3.4% and
18.3% smaller than the cost (4.966) and loss (8.506) of RLSEVC.
Particularly, under the Emax link model, the pattern that MISE varies with n1 indicates
that, the switching point n1 should not be smaller than 30 for the two-stage SLAR, and n1
around 35 could be a good choice for stage-switch. Because of the local linear fit used by
the second stage design, if the number of observations is small, less accurate nonparametric
estimates would adversely affect the precision of estimated dosing function. In addition, the



























































































































































































































































































































































































































































































































































































































performs the worst when the first stage is RLS and produces much better dosing cost and
MISE when the first stage is RLSEVC. According to the loss criterion, we suggest to use
RLSEVC with (δ1, δ2) = (0.3, 3.5) as the first stage design.
Under the Power link model, the general pattern among the numerical results is similar,
only except for the improvements from one-stage RLSEVC to two-stage SLAR are not as
significant as those under the Emax link model. It is probably because the power link curve
is closer to a linear model compared to the Emax link curve, and so the advantages of SLAR
are not highlighted enough. Since the two-stage SLAR with n1 = 40 produces the best MISE,
it would be possible that an ideal switching point sits in between 40 and 35. Therefore, an
extra set of simulation using the two-stage SLAR with n1 = 38 is conducted. The resultant
dosing costs are 4.347, 3.828 and 3.776, meanwhile MISE’s are respectively 0.855, 0.746 and
0.758, corresponding to the first stage being RLS, RLSEVC1 and RLSEVC2 as in Table 4.2.
These results exactly sit in between those of n1 = 40 and n1 = 35, thus it should be better
to switch to SLAR at the end of RLSEVC under the power link model.
Figure 4.5 presents the overall trend in which the dosing cost per each subject varies as
a trial proceeds for the two-stage SLAR under linear and semiparametric models. The first
stage design is RLSEVC with (δ1, δ2) = (0.3, 3.5), and the switching point n1 is selected
at 40, 35, 30 and 25. For n1 = 40, since SLAR is only involved in re-estimation for the
dosing function at the end of Stage 1, the dosing costs are actually the identical to those of
RLSEVC. The upper three sub-figure plot the general trend over an entire trial under the 1st
linear scenario, Emax link and power link models, while the lower three are the zoomed-in
plots that focus on the later half trial, where the design is switched from RLSEVC to SLAR.
The general trend of the individual dosing cost is still similar to that displayed under
linear models. The personal cost starts with increasing slightly at the first several subjects,
then decreases dramatically around the 10th subject, and turns to approach 0 slowly in the































































































































consistent, and the cost paid by the early subjects benefit those in later trial greatly.
From the zoomed-in plots, it would be interesting to find that, at each switching point
smaller than 40, the individual dosing cost drops downwards clearly when switching from
RLSEVC to SLAR. It indicates that switching from RLSEVC to SLAR can help further
reduce the dosing cost. For example, under the Emax link model, the overall dosing cost per
person of SLAR is further lowered down to 0.01 for the last 10 subjects in a trial. Considering
of the small trial size and the complicated semiparametric recursion algorithms, the dosing
accuracy is impressive indeed.
In summary, the simulation study demonstrates that, the two-stage semiparametric link-
adapted recursion design is more robust to link misspecification than the repeated least
squares procedure while trades very limited precision for the improved robustness. When the
true model is semiparametric with an unknown link, the performance of two-stage SLAR is
better than the repeated least squares procedure in terms of dosing cost and MISE, although
RLSEVC already performs acceptably well under link misspecification. We advocate the use
of RLSEVC with (δ1, δ2) = (0.3, 3.5) as the first stage design, meanwhile the switching point
n1 should be chosen close to n. For instance, n1 could be chosen between 35 and 40 for n = 40
at our case. In real-world practice, where the true model is never known, a conservative but
reliable strategy would be, to use RLSEVC at the first stage design and, at its end, apply
SLAR to re-estimate the dosing function. Based on the simulation results under both linear
and semiparametric models, the loss corresponding to this design would be very close to the
smallest loss among all.
4.5 Theoretical Results
The primary estimation interests within the procedure of SLAR are estimation of the direc-
tion parameter φ and unknown link function g(.). In order to ensure the consistency of dose
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sequence (4.12) recommended by SLAR, it would be necessary that the recursive procedure
results in consistent estimators for both φ0 and s0 = g
−1(t0).
Due to the iterative estimation manner of ISLS, the asymptotic properties should be
decomposed into two parts in general. One part is that, given a consistent estimator of
φ0, the isotonized local linear estimators (4.4) of the link function g(.) and its first order
derivative g′(.) is consistent. The other part is that, given consistent estimators of g(.)
and g′(.), the estimator (4.6) of φ0 obtained by solving the pseudo score equation (4.5) is
consistent. For simplicity, we temporarily only consider the cases without the isotonization.
The major theoretical results are summarized by the following two conjectures.




. Under the semipara-



















∣∣∣ĝ′n(s)− g′(s)∣∣∣ = O(√log nn1/5
)
a.s., (4.21)








, and I∗S is a bounded
closed interval in IS such that s(φ) ∈ I∗S for any φ ∈ I∗φ0 .
Then, the root sequence φ̂n (4.10) to the pseudo score equations (4.5) is weakly consistent
for the true value φ0. 
Conjecture 2 Suppose that Condition 1.1 through 1.4 hold. If the estimator φ̂n is weakly









































































ujK(u)du for j = 0, · · · , 4, and νKj =
∫
ujK2(u)du for j = 0, 1, 2; and,
sup
s∈I∗S












where I∗S is a bounded closed interval in IS such that s(φ) ∈ I∗S for any φ ∈ I∗φ0 . 
Condition 1
1. The unknown link function g(.) is non-decreasing and third time continuously differ-
entiable within a bounded closed interval IS ⊂ (−∞,+∞), where IS is the domain of
g(.). Moreover, g(.) is strictly increasing among a neighborhood of s0 = g
−1(t0).
2. The kernel function K(.) is assumed to a symmetric continuous probability density
function with bounded support. K(.) has up to 4th finite moments, meanwhile K2(.)
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has up to 2nd finite moments.
3. The probability density function f(s) of the index s = x+ φz, f(s) > 0 for any s ∈ IS
and, f(s) and f ′(s) are continuous in IS.
4. The bandwidth h→ 0, nh→ +∞ and nh3 → +∞, as n→ +∞.
Comments 1
1. Given the asymptotic bias (4.22) and variance (4.24), it would be straightforward to






















σ2(µ2K2νK0 − 2µK1µK2νK1 + µ2K1νK2)
nhf(s)(µK0µK2 − µ2K1)2
(4.28)
→ 0, as n→∞.
Therefore, by Chebyshev’s inequality, it can be obtained that the local linear estimator
ĝn(s) is weakly consistent for g(s); and, likewise for the week consistency of ĝ
′
n(s).




(4.28) with respect to the bandwidth h, we can derive






































For Conjecture 1, the goal is to show that a sequence of roots to the following pseudo
















= 0, n = n1, n1 + 1, · · · , (4.30)
where sk(φ) = xk + φzk for k = 1, · · · , n. Thus, the asymptotic theory of estimating
equation estimator would be the natural technique to utilize. However, most existing the-
orems (for example Yuan and Jennrich [1998]) that establish consistency of the estimating
equation estimator assume independence among the observations, or at least independent
observations between subjects for the cases with repeated measurements. For the semipara-
metric link-adapted recursion design, each dose xi (4.13) depends on all the previous data
{(yk, xk, zk)}i−1k=1 via the recursive estimation of s0 and φ0. Furthermore, both the estimates,
ŝ0i and φ̂i, do not have explicit analytic forms, because they are obtained by using numerical
algorithms. These bring with us the major difficulties to determine which type of stochastic
processes the dose sequence belongs to, and then investigate the asymptotic behavior of the
stochastic process.
Fortunately, recent development in the theory of estimating equations with stochastic
processes provides us with a promising method to establish consistency of the root sequence
to the estimating equations (4.30). Kessler et al. [2012] introduce the asymptotic theorems
of estimating functions for martingales and diffusion-type processes in the first chapter of
their book. In this chapter, most often, the estimating equations are for specific types of
stochastic processes, for example a martingale, Markov chain, or stationary process with
certain mixing conditions. In Section 1.10, the authors propose a general theorem for the
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weak consistency of estimating equation estimator for a general stochastic process. By using
the notations in our context, the theorem can be stated as follows.
Lemma 2 (Theorem 1.10.2 of Kessler et al. [2012]) The data {(yk, xk, zk)}nk=1 are ob-
servations from a stochastic process, and the estimator φ̂n obtained by solving the estimating
equation Ŝn(φ0) = 0 is an arbitrary function of the data with value in Iφ. Suppose the exis-
tence of a true parameter φ0 ∈ intIφ (the interior of Iφ), a bounded neighborhood I∗φ0 of φ0




P−→ 0 as n→∞; (4.31)






∣∣∣ P−→ 0, (4.32)
where S∗0 (φ0) 6= 0 a.s..
Then, a sequence φ̂n that is the zero-root to estimating function Ŝn(φ) is weakly consistent
for φ0. Moreover, this root sequence is eventually unique, in the sense that, for any other
root sequence φ̃n to Ŝn(φ) = 0 that is consistent for φ0, P (φ̂n 6= φ̃n)→ 0, as n→∞. 
Based on Lemma 2, we make the Conjecture 1 on the consistency of the root sequence
to the pseudo score equation (4.30), and also have the following sketch of proof for it.
Proof Sketch (Conjecture 1) In order to verify the condition (4.31), we at first decom-







































































































= Sn1(φ)− Ŝn2(φ) + Ŝn3(φ)− Ŝn4(φ),
where Sn1(φ0) = 1n
∑n
k=1 zkg














































, Then, the condition
(4.31) would hold if we could respectively show that Sn1(φ),Ŝn2(φ),Ŝn3(φ) and Ŝn4(φ) con-












′(sk(φ0)), by the model (4.2).








by the Continuous Mapping theorem. In addition, g(s) is strictly increasing at s∞
and g′(s) is continuously differentiable on a bounded closed interval IS, thus g
′(s∞) > 0 and
is bounded by some positive constant Bg′ .
Since {zk} and {εk} are independent with each other and both normally distributed with
E(z1) = µz <∞ and E(ε1) = 0, by the Strong Law of Large Numbers (Theorem B on Page






′(s∞) a.s.−−→ 0, as n→∞.











)} a.s.−−→ 0, it can be shown that
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Sn1(φ0)
a.s.−−→ 0, as n→∞.
For any ε > 0,
P


























































→ 0, as n→∞.
Similarly, it can be shown that P
{∣∣Ŝn3(φ0)∣∣ > ε}→ 0 and P{∣∣Ŝn4(φ0)∣∣ > ε}→ 0. There-
fore, combining Sn1(φ0) = o(1) a.s. and Ŝni(φ0) = op(1) for i = 2, 3, 4, then there is
Ŝn(φ0) = Sn1(φ0)− Ŝn2(φ0) + Ŝn3(φ0)− Ŝn4(φ0)
P−→ 0, as n→∞.
In order to verify the condition (4.32), we at first decompose
dŜn(φ)
dφ

































































































































































































































= S∗n1(φ) + Ŝ∗n2(φ)− Ŝ∗n3(φ)− Ŝ∗n4(φ)− Ŝ∗n5(φ)− Ŝ∗n6(φ)− Ŝ∗n7(φ)− S∗n8(φ).
We define that S∗0 (φ) = S∗∞1(φ)−S∗∞8(φ) for φ ∈ Iφ, where S∗∞1(φ) = limn→∞ S∗n1(φ) and
S∗∞8(φ) = limn→∞ S∗n8(φ). Then, to verify the condition (4.32), we need to show that
sup
φ∈I∗φ0
∣∣Ŝ∗nj(φ)∣∣ P−→ 0, for j = 2, · · · , 7, (4.33)
and derive out the limits of S∗n1(φ) and S∗n8(φ) respectively. With the conditions (4.20) and
(4.21), the result (4.33) can be verified by applying the same technique as used in showing
Ŝn2(φ0)
P−→ 0. 
The uniform convergence condition (4.32) is common for most two-stage semiparametric
estimation methods, where the second stage depends on the first stage of nonparametric
estimators. For example, the Theorem 3 of Yuan and Jennrich [1998] also requires that
the estimating functions are continuous and supφ∈I∗φ0
∣∣Ŝn(φ) − S0(φ)∣∣ P−→ 0 for some limit
function S0(.). In Lemma 2 for stochastic processes, the uniform convergence condition is
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stronger than that of independent random variable case, that is, the condition (4.32) can
imply that supφ∈I∗φ0
∣∣Ŝn(φ) − S0(φ)∣∣ P−→ 0 for a bounded neighborhood I∗φ0 . The condition
(4.31) would requires the consistency of local linear estimators (4.4) along with their cor-
responding point-wise convergence rates. Meanwhile, the condition (4.32) would be more
mathematically challenging to verify, since it requires the uniform convergence rate of the
local linear estimator.
It is worth to point out that, given the MSE convergence rates (4.19) and the uniform
convergence rates (4.20) and (4.21), the challenging parts in showing the Conjecture 1 under
the direction of Lemma 2 is the derivation of limits of Sn1(φ), S∗n1(φ) and S∗n8(φ). And, the
calculation of these limits depends on the type of stochastic processes that the dose sequence
xn recommended by SLAR belongs to, as corresponding version of Law of Large Numbers
should be used according the type of specific processes.
However, the most mathematically challenging part is actually how to obtain the afore-
mentioned convergence rates for the local linear estimator with the dependent data collected
under SLAR, that is, the Conjecture 2. Similar to Theorem 3.1 of Fan and Gijbels [1996],
we conjecture the convergence rates for the asymptotic bias and variance of the local lin-
ear estimators (4.4) under SLAR; and, in the light of Stone [1982], we also conjecture the
uniform convergence rates for the local linear estimators under SLAR.
Proof Sketch (Conjecture 2) Given a consistent φ̂n based on the observations at stage n














k = xk + φ̂nzk for
k = 1, · · · , n and obtain the point-wise estimates of link function and its first order derivative
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In fact, under the cases with independent and identically distributed data, the major
techniques used in deriving the asymptotic bias and variance of local linear estimator typi-
cally include the Taylor expansion, approximation to the sums such as Vnij and Unij, and the
asymptotic theorems that deal with the triangular arrays. For instance, when calculating
the asymptotic bias and variance for either ĝn(s) or ĝ
′
n(s), the following technique is used
























ujK(u)[f(s) + huf ′(s) + o(h)]du
= hjf(s)µKj + h
j+1f ′(s)µK(j+1) + o(h
j+1).
Random variables such as {(sk − s)jKh(sk − s)}nk=1 actually form a independent triangular
array, because the row distribution varies with the bandwidth h, which depends on n such
that h → 0 as n → ∞. So, by verifying the Liapunov’s condition for the array such as
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{(sk−s)jKh(sk−s)}nk=1, one can establish the central limit theorem for the row sum. Based
on the central limit theorem, there is the following approximation, which is also typically
used in deriving the asymptotic variance.
n∑
k=1
(sk − s)jKh(sk − s) = E
( n∑
k=1







(sk − s)jKh(sk − s)
))
However, all of these techniques cannot be applied to the data collected via SLAR, due
to the stochastic dependence among them. If, for simplicity, we assume that all previous
doses are free from truncation by the dosing limits, the estimated index at stage n are
ŝ
(n)
k = xk + φ̂nzk = ŝ0(k−1) + (φ̂n − φ̂k−1)zk, for k = 1, · · · , n (4.35)
The index sequence {ŝ(n)k } itself is a dependent triangular array such that each ŝ
(n)
k depends on
all data prior to stage n through the estimates ŝ0(k−1), φ̂n and φ̂k−1, where the distribution of
each index {ŝ(n)k } is not only different within a row but also varies with n due to the presence
of φ̂n.
As mentioned before, another major difficulty is that the estimates of s0 and φ are
obtained numerically without explicit formulae. Thus, it is hard to determine which type
of stochastic processes the index sequence belongs to, explicitly understand their stochastic
behavior and postulate reasonable assumptions on their distributions. Without knowing
these, it would be hard to determine to use which technique in the theory of stochastic
processes.







, for k = 1, · · · , n, and n = 1, 2, · · ·
}
have to be asymptotically
stable in a certain sense.
Bosq [1996] introduces the theory of nonparametric statistics for stochastic processes,
where the 3rd chapter presents the asymptotic theorems of kernel smoother with strictly
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stationary processes. Although the methodology cannot be applied to our problem directly,
it inspires us that MSE of ĝn(s) and ĝ
′
n(s) (4.34) under SLAR should still converge at the
same rates as those under the independent cases. Because, Theorem 3.1 of Bosq [1996]
states that the MSE of kernel smoother for a stationary process converges at the rate of
n−4/5 which is the same as that of the independent case, if the bandwidth h is selected at
the optimal rate O(n−1/5). It is well known in the nonparametric regression theory that the
local constant estimator, i.e. kernel smoother, converges at the same rate as the local linear
estimator does. Therefore, it would be reasonable to conjecture that the dependence among
data under SLAR would not impact the convergence rate of local linear estimator.
Furthermore, the most challenging part is to establish the uniform convergence (4.26) and
(4.27) of the local linear estimator under SLAR. Under independent case, Stone [1982] the
first time investigates the rate for local linear smoother, which result is utilized frequently
in typical two-stage semiparametric regression estimation. As an extension, Hansen [2008]
obtain the uniform rate for a stationary process with strong mixing condition. Based on the
results of Hansen [2008], we conjecture the uniform convergence rate (4.26) and (4.27) of
local linear estimator for the stochastic array ŝ
(n)
k under SLAR. 
The reason why we make the conjectures is mainly because of the difficulty in determining
the type of stochastic process and explicitly investigating the stochastic behaviors for the




This research is motivated by the need for individualized dosing methods in phase I cancer
clinical trials, where the primary endpoint is a continuous pharmacokinetic (PK) response
and dosage is also continuous. The rationale is that, in the presence of inter-subject PK
variation, the doses adjusted for individual-specific needs should be safer and more effica-
cious than a constant dose that is common for all patients. The patient-specific dosing
scheme aims at accounting for inter-individual variability in metabolizing a drug, and avoid-
ing ethical issues sourced from underdosing or overdosing as much as possible. At first,
under a linear dose-response model, we propose a repeated least squares procedure subject
to a consistency constraint to realize the individualized dosing meanwhile ensuring desirable
estimation precision. In the second, in order to improve the design’s robustness against
link misspecification, we propose a semiparametric link-adapted recursion design to individ-
ualize dose assignments while adapt for an unknown link function, under a more general
semiparametric dose-response model.
This research the first time introduces the eigenvalue condition [Lai and Wei, 1982] into
the model based phase I dose-finding designs. The eigenvalue constraint should be a general
criterion for all parametric model based dose-finding designs, regardless whether they are
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individualized or not. Because, the eigenvalue constraint provides model based dose-finding
designs with an intrinsic mechanism that can exclude the asymptotic singularity and ensure
consistent estimation for model parameters. The eigenvalue constraint can also be potentially
applied to other settings such as multiple covariates and binary toxicity response, as the
stochastic linear regression theory is based on a multiple linear model, and it is extended to
the generalized linear model setting by Chen et al. [1999]. Distinguishing from the “best-
intent” designs which focus on the benefits of concurrent study subjects, RLSEVC balances
the welfare of current subjects and future patients by controlling for convergence rate of
the eigenvalue constraint. The design calibration plays a deterministic role in enabling the
effect of eigenvalue constraint, and optimizing the balance between the current and future
dosing costs. The proposed two-element loss criterion succeeds in selecting out the optimal
design parameters, with which RLSEVC can not only significantly improve the precision of
estimated dosing function, but also sacrifice little dosing costs. For enhanced practicality,
the coherence principle is also introduced into the individualized phase I dose-finding designs
for the first time. We suggest the use of coherence restriction in dose-finding designs, so as
to further reduce dosing costs and avoid ethical concerns in trial implementation.
This research also pioneers in the exploration of semiparametric sequential phase I dose-
finding designs. The proposed semiparametric link-adapted recursion provides a novel ap-
proach that can determine doses according to subjects’ needs, while adapt for unknown link
functions. Following the scheme of this approach, new individualized dose-finding designs
can also be developed under other semiparametric models than the single-index models,
as long as the model and dosing function have reasonable and clear interpretations. The
proposed semiparametric design largely reduces the dependency of model based dose-finding
designs on specific link functions, and thus gains larger applicability and higher robustness in
practices. Comprehensive simulation studies demonstrate that, our proposed semiparamet-
ric design does not trade much performance for its improvement in the robustness against
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link misspecification. Under linear dose-response models, the performance of SLAR is very
close to but reasonably worse than that of RLSEVC; under semiparametric dose-response
models, SLAR can not only significantly improve the estimation precision for the dosing
function, but can also reduce the dosing cost compared to RLSEVC. Based on the numerical
simulations, we suggest that RLSEVC is a reliable choice for the first stage of SLAR; if
there is prior evidence showing a nonlinear true dose-response relationship, then switching
from RLSEVC to the second stage of SLAR close to the trial’s end can achieve ideal dosing
cost and estimation precision; if there is no strong evidence about the non-linearity, then
switching from RLSEVC to SLAR at the trial’s end is still a reliable scheme in practices.
It is worth to mention that, the PK measurements would be available only after the
patients take the treatment. Hence, in order to adjust for PK variability prior to dose as-
signments, these PK measurements must be predicted, and a reliable PK model built based
on sufficient pre-clinical and previous PK studies is necessary. For our proposed designs, the
predicted clearance is obtained based on a prediction model between the irinotecan clearance
and baseline characteristics [van der Bol et al., 2010]. Since the metabolism of irinotecan de-
pends on several enzymes in human bodies, if the specific genotypes that determine function
of these proteins could be identified accurately, it would be also reasonable to tailor dosage
according to the corresponding biomarkers directly. In general, it is critical for individualized
dosing to determine what individual information to adjust for, baseline characteristics, PK
measurements, or biomarkers. However, the necessary intelligence supporting such decisions
would exceed a statistician’s knowledge range. Therefore, close inter-disciplinary collabo-
ration among the doctors, pharmacologists, biologists and statisticians is indispensable for
pooling intelligence together to support such decisions in the individualized dosing.
Unlike most conventional dose-finding methods, our proposed designs are based on a dose-
PK response model, rather than a dose-toxicity response model; and, our method emphasizes
the balance between controlling the current dosing costs and ensuring model estimation pre-
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cision. Actually, due to the rich values of doses, early phase is a golden period to investigate
the dose-PK response relationship during the entire developing course of an anti-cancer drug.
As soon as the trial proceeds to later efficacy-evaluation phases, the doses would be most
often fixed at two or three values. By establishing the Dose - PK response - PD endpoint
relationships, the so-called PKPD model can offer more precise insights regarding a drug’s
efficacy and adverse effects. Such relationships are not only useful in assessing the drug’s
safety in early phases, but also extremely valuable in efficacy evaluation and dose justifica-
tions for the development of a novel anti-cancer drug. Moreover, the dose-finding designs
based on a dose - PK response model has larger generalizability than those based on dose-
toxicity outcome model, due to their applicability to studies on either cytotoxic or molecular
targeted agents. Novel molecular targeted agents are more selective and less toxic. Thus,
they could violate the fundamental assumption of toxicity-based dosing methods, which is
the parallel increasing association between the therapeutic and toxic effects [Booth et al.,
2008]. As a result, escalating dose until dose-limiting toxicity occurs does not necessarily
lead to substantial increase in therapeutic effect, because the maximum efficacy might be
achieved at dosage well below MTD. Therefore, for studies on a molecular targeted agent
whose primary endpoint could be a continuous biomarker, the PK model based dose-finding
designs are more suitable than the traditional toxicity based ones.
In terms of future work to extend this research, first of all, it would be important to
extend the repeated least squares with eigenvalue constraint design to the scenarios where
the primary endpoint is a binary toxicity response and/or the dosage is discrete levels. In
concurrent practices, the binary toxicity response is still one of the major endpoints for phase
I cancer studies, while the continuum of dosage is usual for infusion treatments and the dis-
crete dosage is common for oral drugs. Under a generalized linear model setting, RLSEVC
can be extended to binary response cases with selecting appropriate link functions. However,
the extension from continuous dosage to the discrete cases is not very straightforward. For-
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tunately, to overcome this discrete barrier, Cheung and Elkind [2010] develops a promising
method, the virtual observations, to bridge the continuous and discrete dosage scenarios for
the stochastic approximation procedures. By applying the notion of virtual observations
[Cheung and Elkind, 2010], the major obstacle of extending RLSEVC to account for the
discrete dosage cases can be resolved, while the extension work is worth further systematic
investigations.
At the second, it is worth to investigate the effects of the eigenvalue constraint on com-
monly used dose-finding designs for phase I cancer trials, for instance the continual reassess-
ment method (CRM), and compare their performance with RLSEVC based on the first
extension work. This study would target at demonstrating that the eigenvalue constraint
should be used as a general criterion to ensure the estimation precision and dosing accuracy
for all parametric model based dose-finding designs, no matter whether they are individual-
ized or not.
In the third, it would be also crucial to extend the semiparametric link-adapted recursion
to binary toxicity response and/or discrete dosage cases. Because, based on this extension,
a comprehensive evaluation of the commonly used dose-finding designs’ robustness to link
misspecification can then be investigated with comparison to SLAR, so as to show SLAR’s
advantages on robustness over the commonly used designs. At present, such a comprehensive
study is still missing for phase I dose-finding designs, and would be a meaningful supplement
for assessing the robustness of the commonly used methods in practices.
At last, another significant extension work would be to establish the large sample proper-
ties of the semiparametric link-adapted recursion design. Although convincing finite sample
performance usually is more important for phase I dose-finding designs due to the typical
small sample size, the asymptotic properties can further provide conservative but different
perspectives on evaluating the design’s performance.
In the past decade, the personalized medicine has become a focus of biomedical researches,
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and is deemed as the future of medicine. As a core component, individualized dosing will
inevitably replace the traditional “one-size-fit-all” dosing concept, because its matching to
individual genetic makeup allows for higher safety and efficacy. Individualized dose-finding
trial is indeed the first step on the pathway towards the realization of the personalized
medicine in clinical practices and drug development.
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